homovanillic acid has been researched along with Schizophrenia in 410 studies
Homovanillic Acid: A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid.
homovanillate : A hydroxy monocarboxylic acid anion which is obtained by deprotonation of the carboxy group of homovanillic acid.
homovanillic acid : A monocarboxylic acid that is the 3-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. It is a catecholamine metabolite.
Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We investigated the effects of aripiprazole and blonanserin on clinical symptoms and plasma levels of homovanillic acid (pHVA) and 3-methoxy-4hydroxyphenylglycol in the switching strategy of schizophrenia." | 9.19 | Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia. ( Kanno-Nozaki, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Shiga, T; Yabe, H, 2014) |
| " We examined the effects of the Taq1A polymorphism on the plasma monoamine metabolites during the treatment of schizophrenia with aripiprazole, a DRD2 partial agonist." | 9.16 | Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia. ( Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Mori, A; Niwa, S; Numata, Y; Takeuchi, S; Yang, Q, 2012) |
| "We investigated the effects of aripiprazole on plasma levels of brain-derived neurotrophic factor (BDNF) and catecholamine metabolites in first-episode untreated schizophrenia patients." | 9.16 | Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. ( Atake, K; Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Katsuki, A; Nakamura, J; Tomita, M; Umene-Nakano, W; Yoshimura, R, 2012) |
| "In the treatment of acute schizophrenia, risperidone and aripiprazole are both placed the first line antipsychotics." | 9.16 | Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia. ( Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Takeuchi, S; Watanabe, K, 2012) |
| "This study tested the hypothesis that plasma homovanillic acid (pHVA) levels, a peripheral measure of central dopaminergic activity, would predict the change in memory performance in patients with schizophrenia treated with clozapine." | 9.11 | Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia. ( Jayathilake, K; Kim, CH; Lee, MA; Meltzer, HY; Roy, A; Sumiyoshi, C; Sumiyoshi, T, 2004) |
| "An open-label study was performed to investigate the clinical efficacy and mechanisms of risperidone liquid in ameliorating positive symptoms in the acute phase of schizophrenia." | 9.11 | An open study of risperidone liquid in the acute phase of schizophrenia. ( Egami, H; Goto, M; Kaji, K; Kakihara, S; Kohara, K; Maeda, H; Nakamura, J; Ninomiya, H; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2005) |
| "We have previously reported that risperidone might improve negative symptoms in schizophrenia by influencing noradrenergic neurons." | 9.10 | Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. ( Nakamura, J; Shinkai, K; Ueda, N; Yoshimura, R, 2003) |
| "We have investigated plasma homovanillic acid (pHVA) and 3-methoxy-4-hydroxyphenylglycol (pMHPG) concentrations in 34 DSM-III-R neuroleptic-treated schizophrenic patients who were classified into deficit (n = 14) and nondeficit (n = 20) forms of schizophrenia." | 9.08 | Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia. ( Dollfus, S; Dourmap, N; Ménard, JF; Petit, M; Ribeyre, JM; Thibaut, F, 1998) |
| "The introduction of the atypical neuroleptic, clozapine, has had widespread influence not only on the treatment of the seriously mentally ill patient, but also on new drug development and on hypotheses of the pathophysiology of schizophrenia." | 9.07 | Predictors of clozapine response in schizophrenia. ( Hsiao, JK; Litman, RE; Owen, RR; Pickar, D; Su, TP, 1994) |
| "Twenty-one patients with schizophrenia who met criteria for neuroleptic treatment resistance or intolerance participated in a crossover, placebo-controlled, double-blind comparison of long-term typical neuroleptic and clozapine treatment." | 9.07 | Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. ( Gutierrez, R; Konicki, E; Litman, RE; Owen, RR; Pickar, D; Rapaport, MH, 1992) |
| "Plasma homovanillic acid (HVA) levels were measured hourly for a 24-hour period in 10 patients with schizophrenia during treatment with placebo and fluphenazine." | 9.06 | Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with schizophrenia. ( Doran, AR; Douillet, P; Labarca, R; Pickar, D; Roy, A; Wolkowitz, OM, 1990) |
| "Previous studies have variably reported the efficacy of apomorphine in treatment of schizophrenia and tardive dyskinesia." | 9.05 | Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses. ( Davis, BM; Davis, KL; Horvath, TB; Kendler, KS; Levy, MI; Mathé, AA; Mohs, RC; Trigos, G, 1984) |
| "Aripiprazole has been reported to exert variable effects on cognitive function in patients with schizophrenia." | 7.85 | Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia. ( Atake, K; Beppu, H; Hori, H; Igata, R; Katsuki, A; Konishi, Y; Tominaga, H; Yoshimura, R, 2017) |
| "To study the role of dopamine neurotransmission in schizophrenia and its drug treatment by assessing the relationship of plasma homovanillic acid (pHVA), a major central dopamine metabolite to various clinical parameters in schizophrenic patients." | 7.71 | Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia. ( Peet, M; Ramchand, C; Reynolds, GP; Shah, S; Zhang, ZJ, 2001) |
| "To examine plasma homovanillic acid (pHVA) levels in first-episode schizophrenia, to compare pHVA levels in patients and controls, and to assess the association of pHVA levels with psychopathology and treatment response." | 7.69 | Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response. ( Alvir, J; Amin, F; Chakos, M; Cooper, T; Koreen, AR; Lieberman, J; Loebel, A; Mayerhoff, D, 1994) |
| "Increased noradrenergic activity during chronic dopamine blockade may be an episode marker and may predict relapse within 6 weeks following haloperidol withdrawal in schizophrenia." | 7.69 | Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. ( Agren, H; Gurklis, J; O'Connor, DT; Peters, JL; van Kammen, DP; Yao, JK, 1994) |
| "In the week prior to discontinuation of haloperidol treatment, global behavioral ratings and a lumbar puncture for cerebrospinal fluid monoamine metabolities were obtained in 88 patients with chronic schizophrenia." | 7.69 | Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. ( Gilbertson, MW; Gurklis, JA; Kelley, ME; Peters, JL; van Kammen, DP; Yao, JK, 1995) |
| "Plasma homovanillic acid concentration was assessed in 60 young schizophrenic patients, with and without first-degree relatives with schizophrenia, before treatment, and 3 days after starting haloperidol treatment." | 7.69 | Schizophrenia: gender, family risk, and plasma homovanillic acid. ( Andía, I; Basterreche, E; Dávila, R; Friedhoff, AJ; González-Torres, MA; Guimón, J; Zamalloa, MI; Zumárraga, M, 1995) |
| "In a series of studies tyrosine transport was investigated in patients with schizophrenia." | 7.69 | Tyrosine transport as an indicator of cell membrane dysfunction in schizophrenia. ( Bjerkenstedt, L; Wiesel, FA, 1996) |
| "The dopamine hypotheses of schizophrenia and antipsychotic drug action suggest that the dopamine metabolite homovanillic acid (HVA) should change with drug withdrawal and change in clinical state." | 7.69 | Dopamine turnover in schizophrenia before and after haloperidol withdrawal. CSF, plasma, and urine studies. ( Beuger, M; Kelley, ME; van Kammen, DP; Yao, J, 1996) |
| "The efficacy of mianserin as a supplement in treating chronic schizophrenia was tested in 20 inpatients with schizophrenia who were receiving fixed doses of neuroleptics." | 7.68 | Effects of mianserin on negative symptoms in schizophrenia. ( Imai, T; Kai, S; Kajimura, N; Kaneyuki, H; Mizuki, Y; Suetsugi, M; Yamada, M, 1990) |
| "Measurement of plasma prolactin (PRL) concentration and plasma homovanillic acid (HVA) concentration was performed in 24 patients with schizophrenia during maintenance haloperidol treatment." | 7.68 | Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia. ( Csernansky, JG; Newcomer, JW; Riney, SJ; Vinogradov, S, 1992) |
| "Large doses (960 to 3200 mg/day) of propranolol were taken by eight patients with chronic schizophrenia in a double-blind therapeutic trial." | 7.67 | Effect of propranolol on monoamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia. ( Linnoila, M; Ninan, PT; Scheinin, M; van Kammen, DP, 1984) |
| "Schizophrenic patients with high ventricle brain ratios and cortical brain atrophy, as shown by computerized tomography, had decreased spinal fluid concentrations of homovanillic acid and dopamine-beta-hydroxylase activity." | 7.66 | Dopamine-beta-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy. ( Linnoila, M; Mann, LS; Marder, SR; Ninan, PT; Rieder, RO; Scheinin, M; Sternberg, DE; van Kammen, DP; van Kammen, WB, 1983) |
| "1." | 5.29 | Effectiveness of concomitant setiptiline maleate (Tecipul) on negative symptoms of schizophrenia. ( Inanaga, K; Kuniyoshi, M; Miura, C; Nakamura, J, 1994) |
| "Raclopride was well tolerated." | 5.27 | An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. ( Farde, L; Jansson, P; Sedvall, G; Uppfeldt, G; Wahlen, A; Wiesel, FA, 1988) |
| " In neither patient, the increase in haloperidol dosage affected paranoid symptoms." | 5.26 | [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study]. ( Bianchetti, G; Cuche, H; Loo, H; Morselli, PL; Scatton, B; Zarifian, E, 1982) |
| " We investigated the effects of aripiprazole and blonanserin on clinical symptoms and plasma levels of homovanillic acid (pHVA) and 3-methoxy-4hydroxyphenylglycol in the switching strategy of schizophrenia." | 5.19 | Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia. ( Kanno-Nozaki, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Shiga, T; Yabe, H, 2014) |
| "In the treatment of acute schizophrenia, risperidone and aripiprazole are both placed the first line antipsychotics." | 5.16 | Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia. ( Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Niwa, S; Takeuchi, S; Watanabe, K, 2012) |
| "We investigated the effects of aripiprazole on plasma levels of brain-derived neurotrophic factor (BDNF) and catecholamine metabolites in first-episode untreated schizophrenia patients." | 5.16 | Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients. ( Atake, K; Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Katsuki, A; Nakamura, J; Tomita, M; Umene-Nakano, W; Yoshimura, R, 2012) |
| " We examined the effects of the Taq1A polymorphism on the plasma monoamine metabolites during the treatment of schizophrenia with aripiprazole, a DRD2 partial agonist." | 5.16 | Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia. ( Kanno, K; Katsumi, A; Mashiko, H; Miura, I; Mori, A; Niwa, S; Numata, Y; Takeuchi, S; Yang, Q, 2012) |
| "An open-label study was performed to investigate the clinical efficacy and mechanisms of risperidone liquid in ameliorating positive symptoms in the acute phase of schizophrenia." | 5.11 | An open study of risperidone liquid in the acute phase of schizophrenia. ( Egami, H; Goto, M; Kaji, K; Kakihara, S; Kohara, K; Maeda, H; Nakamura, J; Ninomiya, H; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R, 2005) |
| "This study tested the hypothesis that plasma homovanillic acid (pHVA) levels, a peripheral measure of central dopaminergic activity, would predict the change in memory performance in patients with schizophrenia treated with clozapine." | 5.11 | Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia. ( Jayathilake, K; Kim, CH; Lee, MA; Meltzer, HY; Roy, A; Sumiyoshi, C; Sumiyoshi, T, 2004) |
| "Previous work suggests that individuals with schizophrenia display an altered homovanillic acid (HVA) response to metabolic stress." | 5.11 | Abnormal response to metabolic stress in schizophrenia: marker of vulnerability or acquired sensitization? ( Cavalier, E; Delespaul, P; Gielen, J; Marcelis, M; Van Os, J, 2004) |
| "We have previously reported that risperidone might improve negative symptoms in schizophrenia by influencing noradrenergic neurons." | 5.10 | Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia. ( Nakamura, J; Shinkai, K; Ueda, N; Yoshimura, R, 2003) |
| "We have investigated plasma homovanillic acid (pHVA) and 3-methoxy-4-hydroxyphenylglycol (pMHPG) concentrations in 34 DSM-III-R neuroleptic-treated schizophrenic patients who were classified into deficit (n = 14) and nondeficit (n = 20) forms of schizophrenia." | 5.08 | Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia. ( Dollfus, S; Dourmap, N; Ménard, JF; Petit, M; Ribeyre, JM; Thibaut, F, 1998) |
| "Ketamine (1) produced behaviors similar to the positive and negative symptoms of schizophrenia; (2) elicited alterations in perception; (3) impaired performance on tests of vigilance, verbal fluency, and the Wisconsin Card Sorting Test; (4) evoked symptoms similar to dissociative states; and (5) preferentially disrupted delayed word recall, sparing immediate recall and postdistraction recall." | 5.07 | Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. ( Bowers, MB; Bremner, JD; Charney, DS; Delaney, R; Freeman, GK; Heninger, GR; Karper, LP; Krystal, JH; Seibyl, JP, 1994) |
| "Twenty-one patients with schizophrenia who met criteria for neuroleptic treatment resistance or intolerance participated in a crossover, placebo-controlled, double-blind comparison of long-term typical neuroleptic and clozapine treatment." | 5.07 | Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. ( Gutierrez, R; Konicki, E; Litman, RE; Owen, RR; Pickar, D; Rapaport, MH, 1992) |
| "Plasma prolactin concentration (pPRL), plasma homovanillic acid concentration (pHVA), and symptomatology were measured in 24 male subjects with schizophrenia during maintenance haloperidol treatment." | 5.07 | Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease. ( Csernansky, JG; Newcomer, JW; Riney, SJ; Vinogradov, S, 1992) |
| "The introduction of the atypical neuroleptic, clozapine, has had widespread influence not only on the treatment of the seriously mentally ill patient, but also on new drug development and on hypotheses of the pathophysiology of schizophrenia." | 5.07 | Predictors of clozapine response in schizophrenia. ( Hsiao, JK; Litman, RE; Owen, RR; Pickar, D; Su, TP, 1994) |
| "Plasma homovanillic acid (HVA) levels were measured hourly for a 24-hour period in 10 patients with schizophrenia during treatment with placebo and fluphenazine." | 5.06 | Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with schizophrenia. ( Doran, AR; Douillet, P; Labarca, R; Pickar, D; Roy, A; Wolkowitz, OM, 1990) |
| "Previous studies have variably reported the efficacy of apomorphine in treatment of schizophrenia and tardive dyskinesia." | 5.05 | Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses. ( Davis, BM; Davis, KL; Horvath, TB; Kendler, KS; Levy, MI; Mathé, AA; Mohs, RC; Trigos, G, 1984) |
| "Four patients with chronic schizophrenia of stationary character were studied in order to titrate the lowest dose of thioridazine necessary for symptomatic control when the drug is given in combination with the inhibitor of catecholamine synthesis, metyrosine." | 5.04 | Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind crossover technique. ( Carlsson, A; Roos, BE; Skott, A; Wålinder, J, 1976) |
| "Metabolism of the monoamines dopamine, serotonin and noradrenaline, is altered in the central nervous system of people with schizophrenia, and their major metabolites homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA) and 3-methoxy-4-hydroxyphenylglycol (MHPG), respectively, have been intensively studied as indirect measures of these neurotransmitters in cerebrospinal fluid (CSF)." | 3.88 | No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals. ( Agartz, I; Andreou, D; Hjärpe, J; Jönsson, EG; Sedvall, GC; Söderman, E, 2018) |
| "Aripiprazole has been reported to exert variable effects on cognitive function in patients with schizophrenia." | 3.85 | Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia. ( Atake, K; Beppu, H; Hori, H; Igata, R; Katsuki, A; Konishi, Y; Tominaga, H; Yoshimura, R, 2017) |
| " In the present study, we examined the association between blood levels of 3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), or brain-derived neurotrophic factor (BDNF) and scores on the Wisconsin Card Sorting Test (WCST) in patients with early-stage schizophrenia." | 3.75 | Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia. ( Goto, N; Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Kakeda, S; Korogi, Y; Moriya, J; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R, 2009) |
| "This study evaluates the relationship between plasma homovanillic acid (pHVA) levels, which have been used to study the role of central dopamine in schizophrenia, and the positive/negative syndrome in first episode schizophrenic patients before and after antipsychotic treatment." | 3.75 | Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients. ( Baeza, I; Bernardo, M; Castro-Fornieles, J; de la Serna, E; Deulofeu, R; Goti, J; Salvà, J, 2009) |
| " Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia." | 3.73 | Evidence that brain tissue volumes are associated with HVA reactivity to metabolic stress in schizophrenia. ( Bullmore, E; Hofman, P; Marcelis, M; Suckling, J; van Os, J; Woodruff, P, 2006) |
| "To study the role of dopamine neurotransmission in schizophrenia and its drug treatment by assessing the relationship of plasma homovanillic acid (pHVA), a major central dopamine metabolite to various clinical parameters in schizophrenic patients." | 3.71 | Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia. ( Peet, M; Ramchand, C; Reynolds, GP; Shah, S; Zhang, ZJ, 2001) |
| "In this study, plasma obtained from monozygotic twin pairs discordant for schizophrenia (n = 10) or major affective disorder (n = 3) was assayed for epinephrine, norepinephrine, dihydroxyphenylacetic acid, homovanillic acid, adrencorticotropin hormone, and cortisol." | 3.71 | Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis. ( Bonsall, R; Walder, DJ; Walker, EF, 2002) |
| "The concentration of dopamine (DA) metabolite-homovanillic acid (HVA) in cerebrospinal fluid (CSF) of 40 patients with schizophrenia 27 with epilepsy and 15 controls without disorders of CNS was reported." | 3.70 | [Study on dopamine metabolite in cerebrospinal fluid of schizophrenics and epilepsics]. ( Chen, X; Jiang, S; Liao, W, 1998) |
| "Plasma homovanillic acid (HVA), the major DA metabolite and an indicator of brain DA activity, was measured in nonpsychotic, physically healthy first-degree relatives (n = 55) of schizophrenic probands and in normal subjects (n = 20) without a family history of schizophrenia." | 3.70 | Genetic antecedents of dopamine dysfunction in schizophrenia. ( Amin, F; Davis, KL; Knott, PJ; Siever, LJ; Silverman, JM; Smith, CJ, 1999) |
| "To examine plasma homovanillic acid (pHVA) levels in first-episode schizophrenia, to compare pHVA levels in patients and controls, and to assess the association of pHVA levels with psychopathology and treatment response." | 3.69 | Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response. ( Alvir, J; Amin, F; Chakos, M; Cooper, T; Koreen, AR; Lieberman, J; Loebel, A; Mayerhoff, D, 1994) |
| "The dopamine hypotheses of schizophrenia and antipsychotic drug action suggest that the dopamine metabolite homovanillic acid (HVA) should change with drug withdrawal and change in clinical state." | 3.69 | Dopamine turnover in schizophrenia before and after haloperidol withdrawal. CSF, plasma, and urine studies. ( Beuger, M; Kelley, ME; van Kammen, DP; Yao, J, 1996) |
| "In a series of studies tyrosine transport was investigated in patients with schizophrenia." | 3.69 | Tyrosine transport as an indicator of cell membrane dysfunction in schizophrenia. ( Bjerkenstedt, L; Wiesel, FA, 1996) |
| "The relationship between pretreatment levels of plasma homovanillic acid (pHVA) and the outcome of clozapine treatment was studied in 18 male patients with schizophrenia who were resistant to treatment with conventional neuroleptics." | 3.69 | Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine. ( Hasegawa, M; Jayathilake, K; Meltzer, HY; Sumiyoshi, T, 1997) |
| "In order to investigate the biological mechanisms underlying the clinical efficacy of clozapine, 200 mg/day of clozapine was added to the drug regimens of 19 patients with chronic, anti-psychotic-resistant schizophrenia, and the plasma homovanillic acid (HVA), clozapine concentrations, anti-dopamine D2 and anti-serotonin 5-HT2 receptor activities were measured." | 3.69 | Improvement of schizophrenic symptoms and changes in plasma HVA concentrations, plasma anti-D2 and anti-5-HT2 receptor activities with clozapine. ( Asai, M; Fang, YY; Kanba, S; Nibuya, M; Suzuki, E; Wang, ZC; Yagi, G; Yamada, K; Yan, HG, 1996) |
| "Plasma homovanillic acid concentration was assessed in 60 young schizophrenic patients, with and without first-degree relatives with schizophrenia, before treatment, and 3 days after starting haloperidol treatment." | 3.69 | Schizophrenia: gender, family risk, and plasma homovanillic acid. ( Andía, I; Basterreche, E; Dávila, R; Friedhoff, AJ; González-Torres, MA; Guimón, J; Zamalloa, MI; Zumárraga, M, 1995) |
| "Increased noradrenergic activity during chronic dopamine blockade may be an episode marker and may predict relapse within 6 weeks following haloperidol withdrawal in schizophrenia." | 3.69 | Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. ( Agren, H; Gurklis, J; O'Connor, DT; Peters, JL; van Kammen, DP; Yao, JK, 1994) |
| "In the week prior to discontinuation of haloperidol treatment, global behavioral ratings and a lumbar puncture for cerebrospinal fluid monoamine metabolities were obtained in 88 patients with chronic schizophrenia." | 3.69 | Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia. ( Gilbertson, MW; Gurklis, JA; Kelley, ME; Peters, JL; van Kammen, DP; Yao, JK, 1995) |
| "The dopamine metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC), was found to be decreased in the anterior cingulate cortex of individuals with schizophrenia compared with normal controls." | 3.69 | Decreased DOPAC in the anterior cingulate cortex of individuals with schizophrenia. ( Casanova, MF; Karoum, F; Wyatt, RJ, 1995) |
| "In order to investigate the biological characteristics of deficit syndrome in schizophrenia (Carpenter et al 1988), we examined cerebroventricular ratios (CVRs) and plasma concentrations of homovanillic acid (HVA) in a group of schizophrenic inpatients with deficit syndrome (n = 20) and in a control group of age- and sex-matched schizophrenic inpatients without deficit syndrome (n = 20)." | 3.69 | Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement. ( Asai, M; Kanba, S; Kinoshita, N; Matsuo, Y; Nibuya, M; Sekiya, U; Shintani, F; Suzuki, E; Yagi, G, 1995) |
| "The concentrations of serum tyrosine, phenylalanine and tryptophan have been determined in 23 male neuroleptic-free patients with schizophrenia and 28 male healthy control subjects." | 3.69 | Low concentrations of serum tyrosine in neuroleptic-free schizophrenics with an early onset. ( Hemmings, GP; Ramchand, CN; Wei, J; Xu, H, 1995) |
| "Eleven acutely psychotic patients with schizophrenia or schizoaffective disorder underwent a 5-7 day drug-washout period (with lorazepam allowed) prior to participating in a 6-week controlled dose haloperidol trial." | 3.68 | Haloperidol response and plasma catecholamines and their metabolites. ( Alam, MY; Boshes, RA; Fitzgibbon, ME; Green, AI; Pappalardo, KM; Schildkraut, JJ; Tsuang, MT; Waternaux, C, 1993) |
| "Twenty recently admitted patients with mood-incongruent psychoses underwent 1) interviews with the Schedule for Affective Disorders and Schizophrenia for diagnostic evaluation and symptom profiles, 2) drug-free baseline measurements of CSF neurotensin and homovanillic acid, and 3) close monitoring of a therapeutic trial of haloperidol to determine latency of antipsychotic response." | 3.68 | Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. ( Bissette, G; Garver, DL; Nemeroff, CB; Yao, JK, 1991) |
| "Lateral ventricle enlargement in schizophrenia has been positively correlated with poor premorbid competence, negative symptoms, and poor treatment response and negatively correlated with concentrations of homovanillic acid (HVA), a dopaminergic metabolite." | 3.68 | Lateral ventricle-brain ratio and balance between CSF HVA and 5-HIAA in schizophrenia. ( Caudle, J; Eccard, M; Jewart, RD; Lewine, RR; Pollard, W; Risby, E; Risch, SC; Stipetic, M, 1991) |
| "The efficacy of mianserin as a supplement in treating chronic schizophrenia was tested in 20 inpatients with schizophrenia who were receiving fixed doses of neuroleptics." | 3.68 | Effects of mianserin on negative symptoms in schizophrenia. ( Imai, T; Kai, S; Kajimura, N; Kaneyuki, H; Mizuki, Y; Suetsugi, M; Yamada, M, 1990) |
| "In 8 cases of typical neuroleptic malignant syndrome (NMS), homovanillic acid (HVA), 5-hydroxyindole acetic acid (5-HIAA), noradrenaline (NA), and 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) levels in the cerebrospinal fluid (CSF) were assayed during both the active phase of NMS and after recovery." | 3.68 | Neuroleptic malignant syndrome: a study of CSF monoamine metabolism. ( Ishiguro, T; Nisijima, K, 1990) |
| "Measurement of plasma prolactin (PRL) concentration and plasma homovanillic acid (HVA) concentration was performed in 24 patients with schizophrenia during maintenance haloperidol treatment." | 3.68 | Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia. ( Csernansky, JG; Newcomer, JW; Riney, SJ; Vinogradov, S, 1992) |
| "Plasma homovanillic acid (pHVA) levels were measured in 16 chronically ill patients with schizophrenia who also suffered from tardive dyskinesia, and in a group of 14 chronically ill patients with schizophrenia who did not have tardive dyskinesia." | 3.68 | Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia. ( Barbato, G; de Bartolomeis, A; Monteleone, P; Muscettola, G; Pickar, D, 1990) |
| " Lumbar cerebrospinal fluid (CSF) neurotransmitter metabolite levels for homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenyl glycol (MHPG) were determined in patients with schizophrenia and Alzheimer's disease." | 3.67 | Seasonal variations of human lumbar CSF neurotransmitter metabolite concentrations. ( Davis, KL; Losonczy, MF; Mohs, RC, 1984) |
| "Large doses (960 to 3200 mg/day) of propranolol were taken by eight patients with chronic schizophrenia in a double-blind therapeutic trial." | 3.67 | Effect of propranolol on monoamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia. ( Linnoila, M; Ninan, PT; Scheinin, M; van Kammen, DP, 1984) |
| "In 16 patients with chronic schizophrenia, cerebrospinal fluid (CSF) concentrations of homovanillic acid (HVA) showed a significant negative correlation with computed tomographic measures of brain third ventricle size." | 3.67 | Cerebrospinal fluid HVA, central brain atrophy, and clinical state in schizophrenia. ( Bowden, CL; Contreras, SA; Houston, JP; Javors, MA; Maas, JW; McIntyre, KL, 1986) |
| "5-Hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) were measured in the lumbar cerebrospinal fluid of 57 drug-free female patients with DSM-III diagnoses of major unipolar or bipolar depression (n = 14), schizophrenic disorder (n = 18), alcohol dependence (n = 13) and a group of other disorders (n = 12)." | 3.66 | Amine metabolites and neuroendocrine responses related to depression and suicide. ( Arató, M; Banki, CM, 1983) |
| "5-Hydroxyindoleacetic acid (5-HIAA) and homovanillic acid (HVA) were measured in the spinal fluid of 45 women hospitalized in a psychiatric department for major depression (14 cases), schizophrenia (18 cases) and alcohol dependence (13 cases)." | 3.66 | Relationship between cerebrospinal fluid amine metabolites, neuroendocrine findings and personality dimensions (Marke-Nyman scale factors) in psychiatric patients. ( Arató, M; Banki, CM, 1983) |
| "Schizophrenic patients with high ventricle brain ratios and cortical brain atrophy, as shown by computerized tomography, had decreased spinal fluid concentrations of homovanillic acid and dopamine-beta-hydroxylase activity." | 3.66 | Dopamine-beta-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy. ( Linnoila, M; Mann, LS; Marder, SR; Ninan, PT; Rieder, RO; Scheinin, M; Sternberg, DE; van Kammen, DP; van Kammen, WB, 1983) |
| "Baseline concentrations of homovanillic acid (HVA), 5-hydroxyindole acetic acid (5-HIAA) and MHPG in the cerebrospinal fluid (CSF) were determined in 67 lobotomized and 30 non-lobotomized patients with chronic schizophrenia." | 3.66 | Monoamine metabolite levels in cerebrospinal fluid and brain atrophy in lobotomized schizophrenic patients. ( Hyyppä, S; Kampman, R; Myllylä, V; Ranta, P; Rimón, R; Roos, BE, 1979) |
| "The authors report cerebrospinal fluid (CSF) concentrations of five monoamine metabolites before and after probenecid administration in normal subjects and patients with depression and schizophrenia." | 3.66 | CSF monoamine metabolites in depression and schizophrenia. ( Anderson, PJ; Barchas, JD; Berger, PA; Davis, KL; Faull, KF; Kilkowski, J; Kraemer, H, 1980) |
| "The metabolites of serotonin, dopamine, and norepinephrine, 5-hydroxyindoleacetic acid (5HIAA), homovanillic acid (HVA), and 3-methoxy-4-hydroxy-phenylethylene glycol (MHPG), respectively, were studied in cerebrospinal fluid of patients with acute schizophrenia." | 3.65 | Cerebrospinal fluid amine metabolites in acute schizophrenia. ( Carpenter, WT; Fink, E; Goodwin, FK; Post, RM, 1975) |
| "26 patients with a paranoid-hallucinatory syndrome were treated with a fixed daily dose of haloperidol." | 3.65 | Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol. ( Ackenheil, M; Eben, E; Hippius, H; Rüther, E; Schilkrut, R, 1976) |
| "Treatment with olanzapine for 8 weeks improved both positive and negative symptoms of schizophrenia." | 2.73 | Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients. ( Hori, H; Ida, Y; Ikenouchi, A; Mitoma, M; Nakamura, J; Yamada, Y; Yoshimura, R, 2007) |
| "D-cycloserine was readily absorbed and did not induce side-effects or changes in vital signs and mood scores." | 2.69 | The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. ( Blankenstein, MA; Gispen-de Wied, C; Kahn, RS; Lipsch, C; van Berckel, BN; van Ree, JM; Wynne, HJ, 1998) |
| "Treatment with haloperidol caused initial increases in urinary homovanillic acid (HVA) output that returned toward baseline by the 5th week." | 2.67 | Studies of catecholamine metabolism in schizophrenia/psychosis--II. ( Berman, N; Bowden, CL; Contreras, SA; Javors, MA; Maas, JW; Miller, AL; Seleshi, E; Weintraub, SE, 1993) |
| "Sulpiride was administered in three different daily dosages (starting with 400, 800 or 1200 mg) according to a double blind randomized administration schedule." | 2.66 | Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. ( Alfredsson, G; Wiesel, FA, 1989) |
| " The plasma RHAL:HAL ratios on days 6 and 7 were higher than and positively correlated with those at Tmax after a single dose of HAL and were negatively correlated with the HAL:RHAL ratios at Tmax after a single dose of RHAL." | 2.66 | Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients. ( Chang, WH; Chen, CT; Chen, TY; Hu, WH; Jann, MW; Lam, YW; Lin, SK; Yeh, EK, 1989) |
| "Sulpiride-treated patients with extrapyramidal side effects had significantly higher drug concentrations in serum." | 2.65 | Relationships between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine. ( Alfredsson, G; Bjerkenstedt, L; Edman, G; Härnryd, C; Oxenstierna, G; Sedvall, G; Wiesel, FA, 1984) |
| "Schizophrenia is probably ascribed to perinatal neurodevelopmental deficits, and its onset might be affected by environmental factors." | 1.62 | Preventive role of regular low-intensity exercise during adolescence in schizophrenia model mice with abnormal behaviors. ( Hata, T; Hiraga, T; Koizumi, H; Mouri, A; Nabeshima, T; Oharomari, LK; Okamoto, M; Shima, T; Soya, H; Yook, JS, 2021) |
| "Some individuals with schizophrenia present with a dopamine supersensitivity state (DSS) induced by a long-term administration of excessive antipsychotics; this is recognized as dopamine supersensitivity psychosis (DSP)." | 1.62 | Reduction of dopamine and glycogen synthase kinase-3 signaling in rat striatum after continuous administration of haloperidol. ( Hashimoto, K; Hirose, Y; Iyo, M; Kanahara, N; Kimura, H; Kimura, M; Nangaku, M; Niitsu, T; Oda, Y; Shirayama, Y, 2021) |
| "Patients with schizophrenia have higher rates of mortality than the general population." | 1.37 | Early death and CSF monoamine metabolites in schizophrenia spectrum psychosis. ( Carlborg, A; Jokinen, J; Jönsson, EG; Nordström, AL; Nordström, P, 2011) |
| " Dosage of concurrent neuroleptics was fixed at least 3 weeks prior to the trial and was unchanged throughout the study period." | 1.29 | B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia. ( Inoue, T; Koyama, T; Matsubara, S; Ohmori, T; Yamashita, I, 1993) |
| "Schizophrenia is associated with multiple cognitive deficits which in turn may be related to abnormal dopamine (DA) function." | 1.29 | Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. ( Apter, S; Davidson, M; Davis, KL; Harvey, PD; Kahn, RS; Keefe, RS; Mohs, RC; Neale, JM, 1994) |
| "1." | 1.29 | Effectiveness of concomitant setiptiline maleate (Tecipul) on negative symptoms of schizophrenia. ( Inanaga, K; Kuniyoshi, M; Miura, C; Nakamura, J, 1994) |
| "These 85 subjects with nonorganic psychoses had been previously studied with respect to their response to neuroleptic treatment." | 1.28 | Characteristics of psychotic inpatients with high or low HVA levels at admission. ( Bowers, MB, 1991) |
| "Raclopride was well tolerated." | 1.27 | An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. ( Farde, L; Jansson, P; Sedvall, G; Uppfeldt, G; Wahlen, A; Wiesel, FA, 1988) |
| "Debrisoquin is a drug that suppresses the peripheral formation of homovanillic acid without affecting the central formation." | 1.27 | Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients. ( Davidson, M; Davis, BM; Davis, KL; Freed, LB; Lesser, JC; Losonczy, MF; Mohs, RC; Mykytyn, VV; Powchik, P, 1987) |
| "Homovanillic acid accumulation was decreased in this group." | 1.26 | Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology. ( Peters, JG, 1979) |
| " In neither patient, the increase in haloperidol dosage affected paranoid symptoms." | 1.26 | [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study]. ( Bianchetti, G; Cuche, H; Loo, H; Morselli, PL; Scatton, B; Zarifian, E, 1982) |
| "Thioridazine was administered to 14 patients diagnosed as within the "schizophrenic spectrum" with the result that substantial improvement in psychotic symptoms was achieved while significant extrapyramidal side effects occurred in only 1 patients." | 1.25 | Thioridazine: central dopamine turnover and clinical effects of antipsychotic drugs. ( Bowers, MB, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 203 (49.51) | 18.7374 |
| 1990's | 146 (35.61) | 18.2507 |
| 2000's | 35 (8.54) | 29.6817 |
| 2010's | 20 (4.88) | 24.3611 |
| 2020's | 6 (1.46) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, XP | 1 |
| Zhang, YY | 1 |
| Lu, TL | 1 |
| Lu, Z | 1 |
| Kang, ZW | 1 |
| Sun, YY | 1 |
| Yue, WH | 1 |
| Hori, H | 8 |
| Yoshimura, R | 12 |
| Katsuki, A | 4 |
| Atake, K | 4 |
| Takase, M | 1 |
| Kimura, H | 2 |
| Kanahara, N | 2 |
| Nakata, Y | 1 |
| Iyo, M | 2 |
| Shiga, T | 3 |
| Horikoshi, S | 3 |
| Kanno, K | 3 |
| Kanno-Nozaki, K | 4 |
| Hikita, M | 1 |
| Itagaki, S | 2 |
| Miura, I | 7 |
| Yabe, H | 5 |
| Koizumi, H | 1 |
| Hiraga, T | 1 |
| Oharomari, LK | 1 |
| Hata, T | 1 |
| Shima, T | 1 |
| Yook, JS | 1 |
| Okamoto, M | 1 |
| Mouri, A | 1 |
| Nabeshima, T | 2 |
| Soya, H | 1 |
| Kimura, M | 1 |
| Oda, Y | 1 |
| Nangaku, M | 1 |
| Hirose, Y | 1 |
| Niitsu, T | 1 |
| Shirayama, Y | 1 |
| Hashimoto, K | 1 |
| Hatakeyama, T | 1 |
| Kunii, Y | 1 |
| Kono, S | 1 |
| Oshima, S | 1 |
| Nozaki, K | 1 |
| Suzuki, R | 1 |
| Hjärpe, J | 1 |
| Söderman, E | 2 |
| Andreou, D | 2 |
| Sedvall, GC | 3 |
| Agartz, I | 2 |
| Jönsson, EG | 4 |
| da Silva Alves, F | 1 |
| Bakker, G | 1 |
| Schmitz, N | 1 |
| Abeling, N | 1 |
| Hasler, G | 1 |
| van der Meer, J | 1 |
| Nederveen, A | 1 |
| de Haan, L | 1 |
| Linszen, D | 1 |
| van Amelsvoort, T | 1 |
| Katsumi, A | 3 |
| Mashiko, H | 5 |
| Niwa, S | 6 |
| Hino, M | 1 |
| Ota, T | 1 |
| Watanabe, K | 2 |
| Igata, R | 2 |
| Konishi, Y | 2 |
| Nakamura, J | 11 |
| Comasco, E | 1 |
| Vumma, R | 1 |
| Toffoletto, S | 1 |
| Johansson, J | 1 |
| Flyckt, L | 1 |
| Lewander, T | 1 |
| Oreland, L | 2 |
| Bjerkenstedt, L | 10 |
| Terenius, L | 3 |
| Venizelos, N | 1 |
| Beppu, H | 1 |
| Tominaga, H | 1 |
| Winter, C | 1 |
| Djodari-Irani, A | 1 |
| Sohr, R | 1 |
| Morgenstern, R | 1 |
| Feldon, J | 1 |
| Juckel, G | 1 |
| Meyer, U | 1 |
| Baeza, I | 1 |
| Castro-Fornieles, J | 1 |
| Deulofeu, R | 1 |
| de la Serna, E | 1 |
| Goti, J | 1 |
| Salvà, J | 1 |
| Bernardo, M | 1 |
| Arrúe, A | 4 |
| Dávila, R | 13 |
| Zumárraga, M | 11 |
| Basterreche, N | 4 |
| González-Torres, MA | 4 |
| Goienetxea, B | 1 |
| Zamalloa, MI | 3 |
| Anguiano, JB | 3 |
| Guimón, J | 6 |
| Goto, N | 2 |
| Kakeda, S | 2 |
| Moriya, J | 2 |
| Hayashi, K | 3 |
| Ikenouchi-Sugita, A | 4 |
| Umene-Nakano, W | 4 |
| Ueda, N | 7 |
| Korogi, Y | 2 |
| Nikisch, G | 2 |
| Baumann, P | 2 |
| Kiessling, B | 2 |
| Reinert, M | 1 |
| Wiedemann, G | 2 |
| Kehr, J | 2 |
| Mathé, AA | 6 |
| Piel, M | 1 |
| Roesch, F | 1 |
| Weisser, H | 2 |
| Schneider, P | 1 |
| Hertel, A | 2 |
| Carlborg, A | 1 |
| Jokinen, J | 1 |
| Nordström, AL | 1 |
| Nordström, P | 1 |
| Yoshitake, T | 1 |
| Dávila, W | 1 |
| Inchausti, L | 1 |
| Pérez-Cabeza, L | 1 |
| Fernández-Rivas, A | 1 |
| Bustamante, S | 1 |
| Takeuchi, S | 2 |
| Mori, A | 1 |
| Yang, Q | 1 |
| Numata, Y | 1 |
| Tomita, M | 1 |
| Kucinski, A | 1 |
| Syposs, C | 1 |
| Wersinger, S | 1 |
| Bencherif, M | 1 |
| Stachowiak, MK | 2 |
| Stachowiak, EK | 2 |
| Aymard, N | 3 |
| Viala, A | 2 |
| Clement, MN | 1 |
| Jacquot, M | 1 |
| Vacheron, MN | 1 |
| Gauillard, J | 1 |
| Caroli, F | 2 |
| Oranje, B | 1 |
| Gispen-de Wied, CC | 2 |
| Verbaten, MN | 1 |
| Kahn, RS | 15 |
| Oades, RD | 2 |
| Klimke, A | 1 |
| Henning, U | 1 |
| Rao, ML | 2 |
| Kurachi, M | 5 |
| Shinkai, K | 4 |
| Kaneda, Y | 1 |
| Ohmori, T | 2 |
| Elman, I | 1 |
| Lukas, S | 1 |
| Shoaf, SE | 1 |
| Rott, D | 1 |
| Adler, C | 1 |
| Breier, A | 14 |
| van der Heijden, FM | 1 |
| Tuinier, S | 1 |
| Fekkes, D | 1 |
| Sijben, AE | 1 |
| Verhoeven, WM | 4 |
| Sumiyoshi, T | 7 |
| Roy, A | 12 |
| Kim, CH | 1 |
| Jayathilake, K | 3 |
| Lee, MA | 1 |
| Sumiyoshi, C | 1 |
| Meltzer, HY | 3 |
| Marcelis, M | 2 |
| Cavalier, E | 1 |
| Gielen, J | 1 |
| Delespaul, P | 1 |
| Van Os, J | 4 |
| Kakihara, S | 2 |
| Matsumoto, C | 1 |
| Goto, M | 2 |
| Kaji, K | 2 |
| Yamada, Y | 3 |
| Ohmori, O | 1 |
| Kohara, K | 1 |
| Ninomiya, H | 1 |
| Egami, H | 1 |
| Maeda, H | 1 |
| Jacobsen, JP | 1 |
| Rodriguiz, RM | 1 |
| Mørk, A | 1 |
| Wetsel, WC | 1 |
| Duncan, E | 3 |
| Bollini, AM | 1 |
| Sanfilipo, M | 3 |
| Wieland, S | 3 |
| Angrist, B | 4 |
| Cooper, TB | 4 |
| Rotrosen, J | 4 |
| Klejbor, I | 1 |
| Myers, JM | 1 |
| Hausknecht, K | 1 |
| Corso, TD | 1 |
| Gambino, AS | 1 |
| Morys, J | 1 |
| Maher, PA | 1 |
| Hard, R | 1 |
| Richards, J | 1 |
| Suckling, J | 1 |
| Hofman, P | 1 |
| Woodruff, P | 1 |
| Bullmore, E | 1 |
| Ikenouchi, A | 1 |
| Mitoma, M | 1 |
| Ida, Y | 1 |
| Zabalo, MJ | 2 |
| Brunelin, J | 2 |
| D'amato, T | 2 |
| Dalery, J | 1 |
| Suaud-Chagny, MF | 2 |
| Saoud, M | 2 |
| Cochet, A | 1 |
| Toru, M | 4 |
| Ichikawa, H | 1 |
| Chen, YF | 2 |
| DeLisi, LE | 1 |
| Mirsky, AF | 1 |
| Buchsbaum, MS | 1 |
| van Kammen, DP | 19 |
| Berman, KF | 2 |
| Caton, C | 1 |
| Kafka, MS | 1 |
| Ninan, PT | 5 |
| Phelps, BH | 1 |
| Karoum, F | 7 |
| Krupenina, LB | 1 |
| Vinogradov, MV | 1 |
| Lideman, RR | 1 |
| Zlobina, GP | 1 |
| Mukhin, AG | 1 |
| Bowers, MB | 20 |
| Heninger, GR | 6 |
| Joseph, MH | 1 |
| Waddington, JL | 1 |
| Haracz, JL | 1 |
| Owen, F | 3 |
| Baker, HF | 1 |
| Ridley, RM | 1 |
| Cross, AJ | 2 |
| Crow, TJ | 5 |
| Tripodianakis, J | 1 |
| Markianos, M | 3 |
| Garelis, E | 2 |
| Mann, LS | 2 |
| Sternberg, DE | 2 |
| Scheinin, M | 6 |
| Marder, SR | 3 |
| van Kammen, WB | 6 |
| Rieder, RO | 1 |
| Linnoila, M | 15 |
| Domino, EF | 1 |
| Leckman, JF | 2 |
| Cohen, DJ | 2 |
| Shaywitz, BA | 2 |
| Caparulo, BK | 1 |
| Wode-Helgodt, B | 5 |
| Sedvall, G | 19 |
| Gomes, UC | 1 |
| Shanley, BC | 1 |
| Potgieter, L | 1 |
| Roux, JT | 1 |
| Sturges, JS | 1 |
| Gamaleia, NB | 2 |
| Misionzhnik, EIu | 1 |
| Vertogradova, OP | 1 |
| Krasnov, VN | 1 |
| Salenko, BB | 1 |
| Nemtsov, AV | 1 |
| Kalinin, VV | 1 |
| Wood, PL | 1 |
| Etienne, P | 1 |
| Lal, S | 1 |
| Gauthier, S | 1 |
| Cajal, S | 1 |
| Nair, NP | 1 |
| King, DJ | 2 |
| Cooper, SJ | 2 |
| Liddle, J | 1 |
| Banki, CM | 5 |
| Arató, M | 7 |
| Papp, Z | 4 |
| Kurcz, M | 1 |
| Levy, MI | 3 |
| Davis, BM | 8 |
| Mohs, RC | 12 |
| Trigos, GC | 1 |
| Davis, KL | 22 |
| Magnusson, O | 1 |
| Fowler, CJ | 1 |
| Ross, SB | 2 |
| Schulman, A | 2 |
| Wetterberg, L | 1 |
| Bartfai, A | 2 |
| Levander, SE | 2 |
| Nybäck, H | 3 |
| Berggren, BM | 1 |
| Hindmarsh, T | 1 |
| Wiesel, FA | 12 |
| Waters, RN | 1 |
| Chang, WH | 8 |
| Bartko, J | 1 |
| Cowdry, RW | 1 |
| Ebert, MH | 1 |
| Post, RM | 6 |
| Goodwin, FK | 7 |
| Javaid, JI | 8 |
| Liu, TS | 1 |
| Maas, JW | 9 |
| Davis, JM | 8 |
| Alfredsson, G | 2 |
| Edman, G | 3 |
| Härnryd, C | 5 |
| Oxenstierna, G | 3 |
| Gullberg, B | 4 |
| Jeste, DV | 2 |
| Doongaji, DR | 1 |
| van Ree, JM | 2 |
| Westenberg, HG | 4 |
| Krul, JM | 1 |
| Brouwer, GJ | 1 |
| Thijssen, JH | 1 |
| de Wied, D | 1 |
| van Praag, HM | 2 |
| Ceulemans, DL | 1 |
| Schalling, D | 1 |
| Losonczy, MF | 5 |
| Iselius, L | 1 |
| Gerner, RH | 1 |
| Fairbanks, L | 1 |
| Anderson, GM | 1 |
| Young, JG | 1 |
| Hare, TA | 1 |
| Zimmer, R | 1 |
| Teelken, AW | 1 |
| Cramer, H | 1 |
| Ackenheil, M | 5 |
| Zander, KJ | 1 |
| Fischer, H | 1 |
| Kendler, KS | 4 |
| Trigos, G | 2 |
| Horvath, TB | 5 |
| Pickar, D | 26 |
| Labarca, R | 7 |
| Hommer, D | 2 |
| Everett, D | 1 |
| Paul, SM | 7 |
| Charney, DS | 3 |
| Karson, CN | 1 |
| Kleinman, J | 1 |
| Johns, CA | 2 |
| Swigar, ME | 1 |
| Jatlow, PI | 4 |
| Goicoechea, N | 1 |
| Lautin, A | 1 |
| Stanley, M | 3 |
| Gershon, S | 3 |
| Heckl, K | 1 |
| Karobath, M | 1 |
| Anokhina, IP | 2 |
| Kogan, BM | 1 |
| Cutler, NR | 1 |
| Wyatt, RJ | 6 |
| Scatton, B | 1 |
| Zarifian, E | 1 |
| Bianchetti, G | 1 |
| Cuche, H | 1 |
| Loo, H | 3 |
| Morselli, PL | 1 |
| Kobayashi, K | 2 |
| Koide, Y | 1 |
| Shohmori, T | 3 |
| Schiff, SR | 1 |
| Shibuya, H | 1 |
| Nishikawa, T | 1 |
| Semba, J | 1 |
| Mataga, N | 1 |
| Takashima, M | 1 |
| Berger, PA | 2 |
| Faull, KF | 9 |
| Kilkowski, J | 2 |
| Anderson, PJ | 2 |
| Kraemer, H | 2 |
| Barchas, JD | 2 |
| Andía, I | 7 |
| Basterreche, E | 1 |
| Friedhoff, AJ | 5 |
| Faustman, WO | 6 |
| Ringo, DL | 2 |
| Agren, H | 2 |
| Yao, JK | 8 |
| O'Connor, DT | 2 |
| Gurklis, J | 1 |
| Peters, JL | 4 |
| Harvey, PD | 3 |
| Davidson, M | 20 |
| Keefe, RS | 2 |
| Apter, S | 8 |
| Neale, JM | 1 |
| de las Cuevas Castresana, C | 1 |
| González de Rivera, JL | 1 |
| Kuniyoshi, M | 1 |
| Miura, C | 1 |
| Inanaga, K | 1 |
| Breslin, NA | 1 |
| Suddath, RL | 1 |
| Bissette, G | 2 |
| Nemeroff, CB | 2 |
| Lowrimore, P | 1 |
| Weinberger, DR | 3 |
| Owen, RR | 3 |
| Litman, RE | 3 |
| Hsiao, JK | 3 |
| Su, TP | 1 |
| Szymanski, S | 2 |
| Lieberman, J | 3 |
| Pollack, S | 2 |
| Munne, R | 1 |
| Safferman, A | 1 |
| Kane, J | 3 |
| Kronig, M | 1 |
| Cooper, T | 5 |
| Kitaichi, K | 1 |
| Yamada, K | 3 |
| Hasegawa, T | 1 |
| Furukawa, H | 1 |
| Risch, SC | 4 |
| Csernansky, JG | 9 |
| Newcomer, JW | 3 |
| Jackson, K | 1 |
| Lombrozo, L | 2 |
| Zipursky, R | 1 |
| Pfefferbaum, A | 2 |
| Kelley, ME | 4 |
| Gurklis, JA | 2 |
| Gilbertson, MW | 3 |
| Casanova, MF | 1 |
| Nibuya, M | 5 |
| Kanba, S | 6 |
| Sekiya, U | 2 |
| Suzuki, E | 5 |
| Matsuo, Y | 1 |
| Kinoshita, N | 3 |
| Shintani, F | 3 |
| Yagi, G | 6 |
| Asai, M | 5 |
| Elliott, PJ | 1 |
| Knott, P | 5 |
| Stern, RG | 4 |
| Colison, J | 2 |
| Bartko, JJ | 1 |
| Doran, AR | 10 |
| Konicki, PE | 4 |
| Potter, WZ | 5 |
| Manji, HK | 1 |
| Lewine, RR | 3 |
| Lieberman, JA | 2 |
| Alvir, JM | 1 |
| Mayerhoff, D | 2 |
| Loebel, A | 2 |
| Geisler, S | 2 |
| Chakos, M | 2 |
| Koreen, A | 1 |
| Jody, D | 1 |
| Wei, J | 3 |
| Xu, H | 1 |
| Ramchand, CN | 2 |
| Hemmings, GP | 3 |
| Amin, F | 5 |
| Schmeidler, J | 1 |
| Stern, R | 1 |
| Knott, PJ | 2 |
| Seiler, W | 1 |
| Wetzel, H | 1 |
| Hillert, A | 1 |
| Schöllnhammer, G | 1 |
| Benkert, O | 1 |
| Hiemke, C | 1 |
| Alvir, J | 2 |
| Ramos-Lorenzi, J | 1 |
| Woerner, M | 1 |
| Novacenko, H | 1 |
| Kane, JM | 1 |
| Wolkin, A | 2 |
| Röpcke, B | 1 |
| Eggers, C | 1 |
| Möller, HJ | 1 |
| Adachi, S | 1 |
| Koreen, AR | 1 |
| Ribeyre, JM | 4 |
| Lesieur, P | 2 |
| Varoquaux, O | 2 |
| Dollfus, S | 4 |
| Pays, M | 1 |
| Petit, M | 4 |
| Lin, SK | 5 |
| Chung, MC | 1 |
| Lam, YW | 2 |
| Jann, MW | 3 |
| Waldo, MC | 1 |
| Cawthra, E | 2 |
| Adler, LE | 5 |
| Dubester, S | 1 |
| Staunton, M | 2 |
| Nagamoto, H | 3 |
| Baker, N | 3 |
| Madison, A | 1 |
| Simon, J | 1 |
| Scherzinger, A | 1 |
| Koyama, T | 1 |
| Inoue, T | 1 |
| Matsubara, S | 1 |
| Yamashita, I | 1 |
| Xu, HM | 1 |
| Sharma, RP | 5 |
| Janicak, PG | 4 |
| Faull, K | 3 |
| Miller, AL | 4 |
| Contreras, S | 1 |
| Seleshi, E | 6 |
| True, JE | 1 |
| Bowden, C | 1 |
| Castiglioni, J | 1 |
| Rapaport, MH | 2 |
| Wolkowitz, O | 2 |
| Kelsoe, JR | 1 |
| Pato, C | 1 |
| Krystal, JH | 1 |
| Karper, LP | 1 |
| Seibyl, JP | 1 |
| Freeman, GK | 1 |
| Delaney, R | 1 |
| Bremner, JD | 1 |
| Tuckwell, HC | 1 |
| Koziol, JA | 1 |
| Hwu, HG | 1 |
| Chen, TY | 5 |
| Lung, FW | 3 |
| Chen, H | 1 |
| Lin, WL | 4 |
| Hu, WH | 5 |
| Lin, HN | 1 |
| Chien, CP | 1 |
| Risby, ED | 1 |
| Jewart, RD | 2 |
| Stipetic, M | 2 |
| McDaniel, JS | 1 |
| Caudle, J | 2 |
| Whelton, CL | 1 |
| Gupta, RN | 1 |
| Cleghorn, JM | 1 |
| Ballagh, SR | 1 |
| Davis, OR | 1 |
| Buchanan, RW | 1 |
| Moricle, LA | 1 |
| Munson, RC | 1 |
| Magliozzi, JR | 1 |
| Gietzen, DW | 1 |
| Olson, AM | 1 |
| Maclin, EL | 1 |
| Tuason, VB | 1 |
| Green, AI | 2 |
| Alam, MY | 2 |
| Boshes, RA | 1 |
| Waternaux, C | 2 |
| Pappalardo, KM | 2 |
| Fitzgibbon, ME | 1 |
| Tsuang, MT | 1 |
| Schildkraut, JJ | 2 |
| Steinberg, JL | 1 |
| Garver, DL | 6 |
| Moeller, FG | 1 |
| Raese, JD | 1 |
| Orsulak, PJ | 1 |
| Silva, H | 1 |
| Jerez, S | 1 |
| Ruiz, A | 1 |
| Forray, MI | 1 |
| Gysling, K | 1 |
| Andres, ME | 1 |
| Bustos, G | 1 |
| Castillo, Y | 1 |
| Hono, J | 1 |
| Contreras, SA | 6 |
| Berman, N | 3 |
| Bowden, CL | 7 |
| Javors, MA | 4 |
| Weintraub, SE | 1 |
| Weintraub, S | 1 |
| Sobieraj, JT | 1 |
| Salzman, C | 1 |
| Schatzberg, AF | 1 |
| Hirschowitz, J | 2 |
| Juang, DJ | 1 |
| Chen, LC | 1 |
| Yang, CH | 1 |
| Lane, HY | 1 |
| Gonzalez, MA | 1 |
| Silva, RR | 1 |
| Akiyama, K | 1 |
| Tsuchida, K | 1 |
| Kanzaki, A | 1 |
| Ujike, H | 1 |
| Hamamura, T | 1 |
| Kondo, K | 1 |
| Mutoh, S | 1 |
| Miyanagi, K | 1 |
| Kuroda, S | 1 |
| Otsuki, S | 2 |
| Stein, I | 1 |
| Prell, GD | 1 |
| Green, JP | 1 |
| Elkashef, AM | 1 |
| Khandelwal, JK | 1 |
| Lawson, WB | 1 |
| Jaeger, AC | 1 |
| Kaufmann, CA | 1 |
| Kirch, DG | 3 |
| Fukuda, M | 1 |
| Hiramatsu, K | 1 |
| Hata, A | 1 |
| Nakagome, K | 1 |
| Iwanami, A | 1 |
| Honda, H | 1 |
| Beuger, M | 2 |
| Yao, J | 4 |
| Northoff, G | 1 |
| Wenke, J | 1 |
| Demisch, L | 1 |
| Eckert, J | 1 |
| Gille, B | 1 |
| Pflug, B | 1 |
| Epstein, JI | 1 |
| Roitman, SL | 1 |
| Inosaka, T | 1 |
| Saito, H | 1 |
| Sato, M | 2 |
| Koshikawa, H | 2 |
| Donnelly, CL | 1 |
| McEvoy, JP | 1 |
| Wilson, WH | 1 |
| Narasimhachari, N | 2 |
| Hasegawa, M | 2 |
| Funderburg, LG | 1 |
| Weintraub, ST | 1 |
| Thibaut, F | 2 |
| Dourmap, N | 2 |
| Meloni, R | 1 |
| Laurent, C | 1 |
| Campion, D | 1 |
| Ménard, JF | 3 |
| Mallet, J | 1 |
| Ottong, SE | 1 |
| Ohnishi, K | 1 |
| Ashikari, I | 1 |
| Wang, ZC | 1 |
| Fang, YY | 1 |
| Yan, HG | 1 |
| Brown, AS | 1 |
| Gewirtz, G | 1 |
| Harkavy-Friedman, J | 1 |
| Brébion, G | 1 |
| Amador, XF | 1 |
| Malaspina, D | 1 |
| Gorman, JM | 1 |
| Bulbena, A | 1 |
| Galinowski, A | 2 |
| Poirier, MF | 2 |
| Leyris, A | 1 |
| Beauverie, P | 1 |
| Bourdel, MC | 1 |
| Geijer, T | 1 |
| Gyllander, A | 1 |
| van Berckel, BN | 1 |
| Lipsch, C | 1 |
| Gispen-de Wied, C | 1 |
| Wynne, HJ | 1 |
| Blankenstein, MA | 1 |
| Hatzimanolis, J | 1 |
| Lykouras, L | 1 |
| Oulis, P | 1 |
| Wieselgren, IM | 2 |
| Lindström, LH | 5 |
| Nagamoto, HT | 1 |
| McRae, KA | 1 |
| Huettl, P | 1 |
| Gerhardt, G | 2 |
| Hea, R | 1 |
| Griffith, J | 1 |
| Saitoh, O | 2 |
| Yotsutsuji, T | 2 |
| Itoh, H | 3 |
| Kurokawa, K | 2 |
| Silverman, JM | 1 |
| Siever, LJ | 1 |
| Smith, CJ | 1 |
| Soares, JC | 1 |
| Innis, RB | 1 |
| Jiang, S | 1 |
| Chen, X | 1 |
| Liao, W | 1 |
| Uehara, T | 2 |
| Tanii, Y | 1 |
| Chotai, J | 1 |
| Salander Renberg, E | 1 |
| Kullgren, G | 1 |
| Asberg, M | 1 |
| Kim, YK | 1 |
| Kim, L | 1 |
| Lee, MS | 1 |
| Holcomb, JA | 1 |
| Christensen, JD | 1 |
| Balla, A | 1 |
| Koneru, R | 1 |
| Smiley, J | 1 |
| Sershen, H | 1 |
| Javitt, DC | 1 |
| Scheepers, FE | 1 |
| Zhang, ZJ | 1 |
| Reynolds, GP | 2 |
| Ramchand, C | 1 |
| Peet, M | 1 |
| Shah, S | 1 |
| Walker, EF | 1 |
| Bonsall, R | 1 |
| Walder, DJ | 1 |
| Curzon, G | 2 |
| Kantamaneni, BD | 2 |
| Bartlett, JR | 2 |
| Bridges, PK | 2 |
| Watanabe, S | 1 |
| Kaneno, S | 1 |
| Lindström, L | 1 |
| Johnstone, EC | 3 |
| Longden, A | 3 |
| Bacopoulos, NC | 1 |
| Spokes, EG | 2 |
| Bird, ED | 2 |
| Roth, RH | 1 |
| Nagao, T | 1 |
| Ohshimo, T | 1 |
| Mitsunobu, K | 1 |
| Deakin, JF | 1 |
| Westerink, BH | 1 |
| Korf, J | 1 |
| Wilk, S | 3 |
| Clow, A | 1 |
| Jenner, P | 1 |
| Theodorou, A | 1 |
| Marsden, CD | 1 |
| Angrist, BM | 1 |
| Aronson, M | 1 |
| Gruen, P | 1 |
| Sachar, EJ | 1 |
| Denning, RK | 1 |
| Matthysse, S | 3 |
| Grimm, VE | 1 |
| Roccatagliata, G | 1 |
| Albano, C | 1 |
| Cocito, L | 1 |
| Maffini, M | 1 |
| Moore, D | 1 |
| Tarsy, D | 1 |
| Study, RE | 1 |
| Bunney, W | 1 |
| Gillin, JC | 1 |
| Jimerson, D | 1 |
| Van Kammen, D | 2 |
| Peters, JG | 1 |
| Rimón, R | 1 |
| Roos, BE | 4 |
| Kampman, R | 1 |
| Hyyppä, S | 1 |
| Ranta, P | 1 |
| Myllylä, V | 1 |
| Winblad, B | 1 |
| Bucht, G | 1 |
| Gottfries, CG | 2 |
| Iversen, LL | 1 |
| Mackay, AV | 1 |
| Riley, GJ | 1 |
| Shimizu, T | 1 |
| Murphy, DL | 1 |
| Bunney, WE | 2 |
| Wålinder, J | 3 |
| Skott, A | 2 |
| Carlsson, A | 3 |
| Wallin, L | 1 |
| Fyrö, B | 3 |
| Hoehn, MM | 1 |
| Crowley, TJ | 1 |
| Rutledge, CO | 1 |
| Kirstein, L | 1 |
| Heninger, G | 1 |
| Rüther, E | 1 |
| Schilkrut, R | 1 |
| Eben, E | 1 |
| Hippius, H | 2 |
| Sepping, P | 1 |
| Zabrodin, GD | 1 |
| Turova, ZG | 1 |
| Gerlach, J | 2 |
| Thorsen, K | 1 |
| Fog, R | 1 |
| Subrahmanyam, S | 1 |
| Fink, E | 1 |
| Carpenter, WT | 1 |
| Jimerson, DC | 1 |
| Gordon, EK | 1 |
| Bilder, RM | 1 |
| Keefe, R | 1 |
| Webster, L | 1 |
| Whiteford, HA | 1 |
| Stedman, TJ | 1 |
| Welham, J | 1 |
| Pond, SM | 1 |
| Ohlund, LS | 1 |
| Ohman, A | 1 |
| Konicki, E | 1 |
| Gutierrez, R | 1 |
| Botsis, A | 1 |
| Arvanitis, Y | 1 |
| Heritch, AJ | 1 |
| Volavka, J | 1 |
| Douyon, R | 1 |
| Convit, A | 1 |
| Czobor, P | 1 |
| Waldo, M | 3 |
| Drebing, C | 3 |
| Adler, L | 1 |
| Freedman, R | 4 |
| Mazure, CM | 3 |
| Nelson, JC | 3 |
| Riney, SJ | 2 |
| Vinogradov, S | 2 |
| Pandey, GN | 2 |
| Powchik, P | 4 |
| Warne, P | 1 |
| Kaminsky, R | 3 |
| Jaff, S | 2 |
| Baker, NJ | 2 |
| Bell, J | 1 |
| Hattox, S | 1 |
| Murphy, R | 1 |
| Ishizuki, T | 1 |
| Kohno, H | 1 |
| Nakaki, T | 1 |
| Ko, G | 1 |
| Peters, J | 4 |
| Neylan, T | 2 |
| Shaw, D | 1 |
| Nisijima, K | 1 |
| Ishiguro, T | 1 |
| Degrell, I | 2 |
| Nagy, E | 1 |
| Wolkowitz, OM | 11 |
| Pato, CN | 1 |
| Mizuki, Y | 1 |
| Kajimura, N | 1 |
| Imai, T | 1 |
| Suetsugi, M | 1 |
| Kai, S | 1 |
| Kaneyuki, H | 1 |
| Yamada, M | 1 |
| King, RJ | 2 |
| Moses, JA | 3 |
| Poscher, ME | 1 |
| Klockhoff, I | 1 |
| Svedberg, A | 1 |
| Jibson, M | 1 |
| Risby, E | 1 |
| Eccard, M | 1 |
| Pollard, W | 1 |
| Wik, G | 1 |
| Pontius, E | 1 |
| Gregoire, A | 1 |
| Cooper, M | 1 |
| DuMont, K | 1 |
| Benson, KL | 1 |
| Zarcone, VP | 1 |
| Den Boer, JA | 2 |
| Ravelli, DP | 1 |
| Huisman, J | 1 |
| Ohrvik, J | 1 |
| Khan, RS | 1 |
| Goldstein, M | 2 |
| Kerman, B | 1 |
| Easton, M | 1 |
| Kaminski, R | 1 |
| Powchick, P | 2 |
| Warne, PA | 1 |
| McQueeney, RT | 1 |
| Petrie, EC | 1 |
| Muscettola, G | 1 |
| Barbato, G | 1 |
| de Bartolomeis, A | 1 |
| Monteleone, P | 1 |
| Beinfeld, MC | 1 |
| Yeh, EK | 4 |
| Gerhardt, GA | 2 |
| Franks, R | 1 |
| Douillet, P | 2 |
| Ninan, P | 1 |
| Mazonson, A | 1 |
| Hagenfeldt, L | 1 |
| Jennings, WS | 1 |
| Schulz, SC | 1 |
| Hamer, RM | 1 |
| Friedel, RO | 1 |
| Imazu, Y | 1 |
| Kawabata, M | 1 |
| Song, IS | 1 |
| Saito, T | 1 |
| Ishizawa, H | 1 |
| Tsuchiya, F | 1 |
| Ozawa, H | 1 |
| Takahata, N | 1 |
| Besev, G | 1 |
| Gunne, LM | 1 |
| Brown, GL | 1 |
| Doran, A | 2 |
| Parnetti, L | 1 |
| Gottfries, J | 1 |
| Karlsson, I | 1 |
| Långström, G | 1 |
| Svennerholm, L | 1 |
| Swahn, CG | 1 |
| Leahey, W | 1 |
| Green, DF | 1 |
| Widerlöv, E | 1 |
| Lu, RB | 1 |
| Ko, HC | 1 |
| Lin, YT | 1 |
| Ho, SL | 1 |
| Rosen, J | 1 |
| McAdam, D | 1 |
| Nugent, A | 1 |
| Goetz, KL | 1 |
| Johns, C | 1 |
| Rubinow, DR | 1 |
| Glazer, WM | 1 |
| Lee, CF | 2 |
| Lee, TC | 1 |
| Frecska, E | 4 |
| Bagdy, G | 4 |
| Perenyi, A | 4 |
| Mogyorosy, Z | 1 |
| Vojnik, M | 1 |
| Balla, KZ | 1 |
| Boronow, J | 2 |
| Révai, K | 3 |
| Fekete, MI | 1 |
| Ko, GN | 1 |
| Zhang, LD | 1 |
| Yan, WW | 1 |
| Manero, E | 2 |
| Retuerto, F | 1 |
| Barcena, B | 1 |
| Garcia, A | 1 |
| Guicheney, P | 1 |
| Mignot, E | 1 |
| Meyer, P | 1 |
| Sharma, R | 2 |
| Janicak, P | 2 |
| Comaty, J | 2 |
| Chen, CT | 1 |
| Van Putten, T | 1 |
| Aravagiri, M | 1 |
| Chabert, N | 1 |
| Mintz, J | 1 |
| Rapaport, M | 1 |
| Ferrier, IN | 1 |
| Johnson, JA | 1 |
| Owens, DG | 1 |
| Poulter, M | 1 |
| Awad, AG | 1 |
| Müller-Spahn, F | 1 |
| Zemlan, FP | 1 |
| Hitzemann, RJ | 1 |
| Syvälahti, EK | 1 |
| Hietala, J | 2 |
| Huupponen, R | 1 |
| Pihlajamäki, K | 1 |
| Seppälä, OP | 1 |
| Säkö, E | 1 |
| Morimasa, T | 1 |
| Jaskiw, G | 1 |
| Kelsoe, J | 1 |
| Heh, CW | 1 |
| Potkin, SG | 1 |
| Costa, J | 1 |
| Herrera, J | 1 |
| Sramek, J | 1 |
| DeMet, E | 1 |
| Farde, L | 1 |
| Jansson, P | 1 |
| Uppfeldt, G | 1 |
| Wahlen, A | 1 |
| Schweitzer, JW | 1 |
| Hung, JC | 1 |
| Freed, LB | 2 |
| Lesser, JC | 1 |
| Mykytyn, VV | 1 |
| Narang, PK | 1 |
| Perea, K | 1 |
| Seppala, T | 1 |
| Houston, JP | 1 |
| McIntyre, KL | 1 |
| Giordani, AB | 1 |
| Bridge, TP | 2 |
| Kleinman, JE | 2 |
| Soldo, BJ | 1 |
| Koulu, M | 1 |
| Syvälahti, E | 1 |
| DeNigris, Y | 1 |
| Thomas, JW | 1 |
| Koppelhus, P | 1 |
| Helweg, E | 1 |
| Monrad, A | 1 |
| Sourkes, TL | 1 |
| Beckmann, H | 2 |
| Hoffmann, G | 2 |
| Markianos, E | 2 |
| Nyström, I | 1 |
| Raese, J | 2 |
| Sathananthan, G | 1 |
| Fri, CG | 2 |
| Rosenblatt, S | 1 |
| Leighton, WP | 1 |
| Chanley, JD | 1 |
| Bürki, HR | 1 |
| Ruch, W | 1 |
| Asper, H | 1 |
| Baggiolini, M | 1 |
| Stille, G | 1 |
| Borg, S | 1 |
| Greil, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in First Episode Untreated Schizophrenia: A Randomized, Open Label, Active Controlled Study[NCT03304457] | Phase 4 | 100 participants (Actual) | Interventional | 2017-08-25 | Completed | ||
| Prematurity as Predictor of Children's Cardiovascular-renal Health (PREMATCH)[NCT02147457] | 180 participants (Actual) | Observational | 2014-10-31 | Completed | |||
| [NCT00004325] | 200 participants | Observational | 1988-12-31 | Completed | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| A Randomized Trial Administering Estradiol Patch vs. Placebo Patch as add-on to Antipsychotics in Female Patients Above the Age of 38 With Schizophrenia, Schizoaffective or Schizophreniform Disorder[NCT04093518] | Phase 3 | 100 participants (Anticipated) | Interventional | 2019-12-02 | Recruiting | ||
| Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder[NCT03748446] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2019-12-05 | Recruiting | ||
| Efficacy of Rapid-Acting NMDA Antagonist for Treatment of Adolescent Depression and Anxiety Disorders[NCT02579928] | Phase 4 | 17 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Measurement of GABA and Neurosteroid Levels in Women With Menopausal Major Depression Before and After Treatment With Estrogen Alone, Fluoxetine Alone, or Estrogen and Fluoxetine and Normal Controls Before and After Treatment With Estrogen[NCT00626340] | Phase 4 | 18 participants (Actual) | Interventional | 1999-07-31 | Completed | ||
| Changes of the Short Portable Mental Status Questionnaire (SPMSQ-E) After Ketamine Administration on Ophthalmic Surgery in Geriatric Population.[NCT02049411] | Phase 2 | 80 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia[NCT03323437] | Phase 4 | 47 participants (Actual) | Interventional | 2017-09-15 | Completed | ||
| Ketamine for Severe Adolescent Depression: Intermediate-term Safety and Efficacy[NCT03889756] | Phase 2/Phase 3 | 3 participants (Actual) | Interventional | 2019-07-17 | Terminated (stopped due to No more funding available to continue since we could not recruit throughout the pandemic.) | ||
| Clozapine Response and Biogenic Amines in Schizophrenia[NCT00169039] | Phase 4 | 66 participants | Interventional | 1994-12-31 | Terminated | ||
| Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia[NCT00156715] | Phase 4 | 23 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Aripiprazole Effects on Reward Processing in Deficit Syndrome Schizophrenia[NCT00209027] | 20 participants (Actual) | Interventional | 2005-04-30 | Terminated (stopped due to difficulty with technical aspect of fMRI, resources to complete the study ran out) | |||
| Risperidone Long-Acting for Alcohol and Schizophrenia Treatment (R-LAST)[NCT00130923] | Phase 4 | 95 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
"Depressive symptoms (measured by Montgomery-Asberg Depression Rating Scale, revised (MADRS) score) on 1 day after infusion, for the cohort of subjects enrolled in the MDD arm of this trial.~Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60.~Usual cutoff points are:~0 to 6 - normal /symptom absent. 7 to 19 - mild depression. 20 to 34 - moderate depression. >34 - severe depression." (NCT02579928)
Timeframe: 1 day after the infusion
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine | 15.44 |
| Midazolam | 24.13 |
"This study was conducted at Yale University almost two decades ago. Our group at the University of Pennsylvania only has very basic information about this study. This includes the number of participants, which was 18, and the fact that no adverse events occurred. Staff members at the University of Pennsylvania do not have access to any additional study data. The contact person who initially entered this study protocol information is no longer at the University of Pennsylvania and we are unable to contact for additional information.~We only know that 18 participants completed, but as far as we know data was never analyzed for these 18 participants." (NCT00626340)
Timeframe: Healthy controls will undergo scans pre and post 3 weeks of estrogen treatment. Women with depression will undergo scans pre and post 6 weeks of treatment with estrogen alone, estrogen and fluoxetine, or fluoxetine alone
| Intervention | () |
|---|---|
| All Participants | 0 |
Establish if repeated ketamine will be efficacious medically and psychiatrically, as measured by a significant reduction in CDRS score in those treated with ketamine at the end of the dosing paradigm. The Children's Depression Rating Scale (CDRS) is a clinician-rated instrument with 17 items scored on a 1 to 5 or 1 to 7 scale. A rating of 1 indicates normal, thus the minimum score is 17. The maximum score is 113. Scores of 20-30 suggest borderline depression. Scores of 40-60 indicate moderate depression. (NCT03889756)
Timeframe: Day 18
| Intervention | score on a scale (Mean) |
|---|---|
| Ketamine | 42 |
| Midazolam | 62 |
Establish if repeated ketamine will be tolerated as measured by drop-out counts. (NCT03889756)
Timeframe: Day 18
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine | 0 |
| Midazolam | 0 |
The main outcome measure of clinical symptoms was the Positive and Negative Symptoms Scale. This is a 30 item scale for assessing patients diagnosed with schizophrenia. Each item is rated on a 1 (absent) to 7 (extreme) scale. The minimum total score is 30 and the maximum is 210. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| QUET | 65.5 |
Timeline Follow-back (TLFB) procedure was used at screening and baseline to establish current substance use, and it was also used weekly during the course of the study to assess continued alcohol and other substance use. TLFB cosisted of using a calendar and sasking participants to report alcohol and other drug use since last visit. At the screening visit, the TLFB was done for the four weeks prior to the visit. (NCT00156715)
Timeframe: 12 Weeks
| Intervention | Drinking Days per Week (Mean) |
|---|---|
| QUET | 2.7 |
Frequency of drinking days is obtained each week retrospectively as the number of drinking days during the prior week (assessed using the Timeline Followback). Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 2.84 |
| Oral Risperidone Aka Risperdal | 3.46 |
A rater assesses social, occupational and psychological functioning on a hypothetical continuum of mental health - illness (using Global Assessment of Functioning); scores range from 100 to 1, where higher values represent a better outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of impairment (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 50.8 |
| Oral Risperidone Aka Risperdal | 49.9 |
A rater assesses positive and negative symptoms of schizophrenia using a 30-item scale (Positive and Negative Symptom Score) Scores range from 30 to 210, where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal severity of symptoms (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 78.2 |
| Oral Risperidone Aka Risperdal | 75.5 |
A rater assesses the severity of illness and global impression using a scale from 1 to 7 (Clinical Global Impression), where higher values represent a worse outcome. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | ordinal unit of severity (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 4.02 |
| Oral Risperidone Aka Risperal | 3.96 |
Frequency of heavy drinking days is obtained each week retrospectively as the number of heavy drinking days during the prior week (assessed by the Timeline Followback Scale). A heavy drinking day is defined as 4 or more drinks per day for a female and 5 or more drinks per day for a male. Mixed models are used to obtain estimates of efficacy from the partial data provided by each subject while adherent to assigned treatment (under the 'missing at random' assumption). The 'explanatory' estimands (target of the mixed model estimation) are defined in terms of population quantities that would have occurred had all subjects remained on assigned treatment throughout the study. The point estimate for each arm is reported under Number. (NCT00130923)
Timeframe: 6 months
| Intervention | heavy drinking days per week (Number) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | -.11 |
| Oral Risperidone Aka Risperal | .68 |
Number of participants with medication adherence (defined as taking medication at least 75% of the days in the treatment period). (NCT00130923)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Risperidone Long Acting Injectable (LAI) | 43 |
| Oral Risperidone Aka Risperdal | 28 |
31 reviews available for homovanillic acid and Schizophrenia
| Article | Year |
|---|---|
Pathogenesis of schizophrenia: Part II. Temporo-frontal two-step hypothesis.
Topics: Amygdala; Animals; Disease Models, Animal; Dopamine; Entorhinal Cortex; Frontal Lobe; Homovanillic A | 2003 |
[Neurotransmitters and neuropeptides in schizophrenia].
Topics: Acetylcholine; Brain Chemistry; Endorphins; Enkephalins; Homovanillic Acid; Humans; Hydroxyindoleace | 1984 |
[Problem of neuronal reception and the dopamine hypothesis of schizophrenia].
Topics: Adenylyl Cyclase Inhibitors; Animals; Antipsychotic Agents; Apomorphine; Blood Platelets; Brain; Bro | 1980 |
[Biological methods of predicting the effectiveness of psychopharmacologic treatment of schizophrenia (review)].
Topics: Antipsychotic Agents; Apomorphine; Cyclic AMP; Drug Evaluation; Electroencephalography; Evoked Poten | 1981 |
Cerebrospinal fluid probenecid studies: a reinterpretation.
Topics: Biological Transport; Brain; Depressive Disorder; Dopamine; Homovanillic Acid; Humans; Hydroxyindole | 1983 |
Genetic studies of CSF monoamine metabolites.
Topics: Biogenic Amines; Blood Platelets; Dopamine beta-Hydroxylase; Female; Homovanillic Acid; Humans; Hydr | 1984 |
[Etiology of schizophrenia: neurochemical aspects].
Topics: Antipsychotic Agents; Dopamine Antagonists; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mon | 1994 |
Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review.
Topics: Antidepressive Agents; Antipsychotic Agents; Brain; Dopamine; Homovanillic Acid; Humans; Monoamine O | 1994 |
Predictors of response to neuroleptic treatment in schizophrenia.
Topics: Antipsychotic Agents; Brain; Electroencephalography; Homovanillic Acid; Humans; Neuropsychological T | 1993 |
A meta-analysis of homovanillic acid concentrations in schizophrenia.
Topics: Dopamine; Female; Homovanillic Acid; Humans; Male; Schizophrenia | 1993 |
Clozapine response and plasma catecholamines and their metabolites.
Topics: Adult; Brain; Catecholamines; Clozapine; Dose-Response Relationship, Drug; Female; Homovanillic Acid | 1993 |
Clozapine response and plasma catecholamines and their metabolites.
Topics: Adult; Brain; Catecholamines; Clozapine; Dose-Response Relationship, Drug; Female; Homovanillic Acid | 1993 |
Clozapine response and plasma catecholamines and their metabolites.
Topics: Adult; Brain; Catecholamines; Clozapine; Dose-Response Relationship, Drug; Female; Homovanillic Acid | 1993 |
Clozapine response and plasma catecholamines and their metabolites.
Topics: Adult; Brain; Catecholamines; Clozapine; Dose-Response Relationship, Drug; Female; Homovanillic Acid | 1993 |
Neurochemical brain imaging investigations of schizophrenia.
Topics: Aspartic Acid; Brain; Corpus Striatum; Dopamine; Glutamic Acid; Homovanillic Acid; Humans; Magnetic | 1999 |
[Biological approaches to acute psychoses].
Topics: Acute Disease; Antipsychotic Agents; Brain; Cognition Disorders; Homovanillic Acid; Humans; Magnetic | 1999 |
[Dopamine hypothesis in schizophrenia--recent findings in limbic system abnormality].
Topics: Antipsychotic Agents; Dopamine; Homovanillic Acid; Humans; Limbic System; Receptors, Dopamine; Schiz | 1978 |
[Schizophrenia and dopamine (author's transl)].
Topics: Amphetamines; Animals; Antipsychotic Agents; Brain; Dopamine; Dopamine Antagonists; Extrapyramidal T | 1978 |
Dopamine and schizophrenia.
Topics: Amphetamines; Antipsychotic Agents; Brain; Dopamine; Glutamate Decarboxylase; Homovanillic Acid; Hum | 1978 |
[Current biochemical conceptions of mental disorders. I. Biogenic amines in the pathogenesis of schizophrenia].
Topics: Animals; Biogenic Amines; Blood Platelets; Brain Chemistry; Catechol O-Methyltransferase; Disease Mo | 1979 |
Studies of amine metabolites in affective illness and in schizophrenia: a comparative analysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Antidepressive Agents, Tricyclic; Bipolar Disorder; Brain; Depressio | 1975 |
Structure-function relations in schizophrenia: brain morphology and neuropsychology.
Topics: Brain; Cerebral Ventricles; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Psych | 1992 |
Homovanillic acid measurement in clinical research: a review of methodology.
Topics: Body Fluids; Brain Diseases; Female; Homovanillic Acid; Humans; Male; Schizophrenia | 1992 |
Dopamine in schizophrenia: a review and reconceptualization.
Topics: Animals; Antipsychotic Agents; Brain; Cognition; Dopamine; Frontal Lobe; Homovanillic Acid; Humans; | 1991 |
Dopamine in schizophrenia: a review and reconceptualization.
Topics: Animals; Antipsychotic Agents; Brain; Cognition; Dopamine; Frontal Lobe; Homovanillic Acid; Humans; | 1991 |
Dopamine in schizophrenia: a review and reconceptualization.
Topics: Animals; Antipsychotic Agents; Brain; Cognition; Dopamine; Frontal Lobe; Homovanillic Acid; Humans; | 1991 |
Dopamine in schizophrenia: a review and reconceptualization.
Topics: Animals; Antipsychotic Agents; Brain; Cognition; Dopamine; Frontal Lobe; Homovanillic Acid; Humans; | 1991 |
Measurement of plasma homovanillic acid concentrations in schizophrenic patients.
Topics: Biomarkers; Circadian Rhythm; Diet; Homovanillic Acid; Humans; Physical Exertion; Schizophrenia | 1990 |
Cerebrospinal fluid studies of monoamine metabolism in schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Antipsychotic Agents; Catecholamines; Cyclic AMP; Dopamine; Dopamine | 1986 |
A critical appraisal of CSF monoamine metabolite studies in schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Biogenic Monoamines; Dopamine; Homovanillic Acid; Humans; Hydroxyind | 1988 |
Dopaminergic balance and subtypes of schizophrenia.
Topics: Brain; Dopamine; Homovanillic Acid; Humans; Schizophrenia; Schizophrenic Psychology | 1989 |
Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia.
Topics: Brain; Dopamine; Homovanillic Acid; Humans; Limbic System; Receptors, Dopamine; Schizophrenia | 1989 |
Neuroendocrinological and biochemical effects of chronic neuroleptic treatment.
Topics: Adult; Antipsychotic Agents; Apomorphine; beta-Endorphin; Drug Tolerance; Endocrine System Diseases; | 1985 |
Perspectives on a time-dependent model of neuroleptic action.
Topics: Antipsychotic Agents; Brain; Homovanillic Acid; Humans; Methoxyhydroxyphenylglycol; Receptors, Dopam | 1988 |
Plasma homovanillic acid as an index of central dopaminergic activity: studies in schizophrenic patients.
Topics: Animals; Antipsychotic Agents; Brain; Cerebral Cortex; Debrisoquin; Dopamine; Homovanillic Acid; Hum | 1988 |
Implications of catecholamine systems of the brain in schizophrenia.
Topics: Amphetamine; Brain; Catecholamines; Chlorpromazine; Dihydroxyphenylalanine; Dopamine; Histamine H1 A | 1974 |
Antipsychotic drug actions: a clue to the neuropathology of schizophrenia?
Topics: Animals; Basal Ganglia Diseases; Brain; Butyrophenones; Cognition; Dogs; Dopamine; Haplorhini; Homov | 1973 |
81 trials available for homovanillic acid and Schizophrenia
| Article | Year |
|---|---|
Dopaminergic modulation of the reward system in schizophrenia: a placebo-controlled dopamine depletion fMRI study.
Topics: Adult; alpha-Methyltyrosine; Anticipation, Psychological; Brain; Brain Mapping; Dopamine; Double-Bli | 2013 |
Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Female; Homovanilli | 2014 |
Relationship between dopamine D2 receptor occupancy, clinical response, and drug and monoamine metabolites levels in plasma and cerebrospinal fluid. A pilot study in patients suffering from first-episode schizophrenia treated with quetiapine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antipsychotic Agents; Benzamides; Biogenic Monoamines; Brain | 2010 |
Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
Topics: Acute Disease; Adult; Alleles; Antipsychotic Agents; Aripiprazole; Female; Genetic Carrier Screening | 2012 |
Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain-Derived Neurotrophic Factor; Case-Control Studies; | 2012 |
Effect of switching to risperidone after unsuccessful treatment with aripiprazole on plasma monoamine metabolites level in the treatment of acute schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Fema | 2012 |
Modulating sensory gating in healthy volunteers: the effects of ketamine and haloperidol.
Topics: Adult; Antipsychotic Agents; Blood Pressure; Cross-Over Studies; Double-Blind Method; Electroencepha | 2002 |
Plasma levels of homovanillic acid and the response to risperidone in first episode untreated acute schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Female; Homovanillic Acid; Humans; Mal | 2003 |
Impact of risperidone medication on quality of life and gonadal axis hormones in schizophrenia male patients with acute exacerbation.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Gonadal Steroid Hormones; Homovanillic Acid; Hu | 2003 |
Atypical antipsychotics and the relevance of glutamate and serotonin.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Case-Control Studies; Chromatography, High Pressu | 2004 |
Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia.
Topics: Adult; Clozapine; Homovanillic Acid; Humans; Male; Memory; Predictive Value of Tests; Psychomotor Pe | 2004 |
Abnormal response to metabolic stress in schizophrenia: marker of vulnerability or acquired sensitization?
Topics: Adolescent; Adult; Antimetabolites; Blood Glucose; Case-Control Studies; Deoxyglucose; Female; Genet | 2004 |
An open study of risperidone liquid in the acute phase of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Chromatography, High Pressure Liquid; | 2005 |
Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Catecholamines; Cyt | 2007 |
Serotonergic response to stress: a protective factor against abnormal dopaminergic reactivity in schizophrenia?
Topics: Adult; Antimetabolites; Arousal; Cross-Over Studies; Deoxyglucose; Dopamine; Double-Blind Method; Fe | 2007 |
The effect of propranolol on CSF amine metabolites in psychiatric patients.
Topics: Adult; Chronic Disease; Clinical Trials as Topic; Female; Glycols; Homovanillic Acid; Humans; Hydrox | 1983 |
Relationships between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine.
Topics: Adolescent; Adult; Chlorpromazine; Clinical Trials as Topic; Double-Blind Method; Female; Homovanill | 1984 |
Clinical, biochemical, and hormonal aspects of treatment with Des-tyr1-gamma-endorphin in schizophrenia.
Topics: Adolescent; Adult; Clinical Trials as Topic; Double-Blind Method; Endorphins; Female; Growth Hormone | 1984 |
Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
Topics: Adult; Apomorphine; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Growth Hormone; Homovanillic | 1984 |
Lithium prevents adaptation of brain dopamine systems to haloperidol in schizophrenic patients.
Topics: Adult; Brain; Drug Therapy, Combination; Drug Tolerance; Female; Haloperidol; Homovanillic Acid; Hum | 1983 |
Apomorphine and schizophrenia.
Topics: Adult; Apomorphine; Dyskinesia, Drug-Induced; Homovanillic Acid; Hormones; Humans; Male; Middle Aged | 1984 |
Sodium valproate in schizophrenia: some biochemical correlates.
Topics: Adult; Clinical Trials as Topic; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Male; Methoxyhy | 1980 |
Low-dose apomorphine reduces serum homovanillic acid concentrations in schizophrenic patients.
Topics: Adult; Apomorphine; Female; Gas Chromatography-Mass Spectrometry; Homovanillic Acid; Humans; Male; P | 1982 |
Predictors of clozapine response in schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Double-Blind Method; Female; Fluphen | 1994 |
The dopamine-serotonin relationship in clozapine response.
Topics: Adolescent; Adult; Antipsychotic Agents; Clozapine; Dopamine; Drug Resistance; Dyskinesia, Drug-Indu | 1993 |
Effects of raclopride treatment on plasma and CSF HVA: relationships with clinical improvement in male schizophrenics.
Topics: Adult; Dopamine Antagonists; Double-Blind Method; Homovanillic Acid; Humans; Hydroxyindoleacetic Aci | 1994 |
Plasma levels of benperidol, prolactin, and homovanillic acid after intravenous versus two different kinds of oral application of the neuroleptic in schizophrenic patients.
Topics: Administration, Oral; Adult; Benperidol; Cross-Over Studies; Female; Homovanillic Acid; Humans; Inje | 1994 |
Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia.
Topics: Adolescent; Adult; Blinking; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Follow-Up Studie | 1994 |
Acute effects of neuroleptics on unmedicated schizophrenic patients and controls.
Topics: Adult; Antipsychotic Agents; Brain; Debrisoquin; Dopamine; Haloperidol; Homovanillic Acid; Humans; M | 1993 |
Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hom | 1993 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Topics: Adult; Blood Pressure; Cognition; Dissociative Disorders; Dose-Response Relationship, Drug; Double-B | 1994 |
Memory and plasma HVA changes in schizophrenia: are they episode markers?
Topics: Adult; Biomarkers; Cognition Disorders; Double-Blind Method; Haloperidol; Homovanillic Acid; Humans; | 1994 |
Plasma homovanillic acid and treatment response in a large group of schizophrenic patients.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flupenthi | 1993 |
Plasma homovanillic acid in neuroleptic responsive and nonresponsive schizophrenics.
Topics: Adult; Analysis of Variance; Dose-Response Relationship, Drug; Drug Administration Schedule; Haloper | 1993 |
Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia. Relationship to prefrontal cortex volume.
Topics: Adult; Blood Pressure; Deoxyglucose; Dopamine; Double-Blind Method; Female; Frontal Lobe; Heart Rate | 1993 |
Differential effects of haloperidol on negative symptoms in drug-naive schizophrenic patients: effects on plasma homovanillic acid.
Topics: Adolescent; Adult; Affect; Arousal; Attention; Brain; Dose-Response Relationship, Drug; Double-Blind | 1993 |
Studies of catecholamine metabolism in schizophrenia/psychosis--II.
Topics: Adult; Aged; Analysis of Variance; Catecholamines; Circadian Rhythm; Haloperidol; Homovanillic Acid; | 1993 |
Studies of catecholamine metabolism in schizophrenia/psychosis--I.
Topics: Adult; Aged; Analysis of Variance; Blood Platelets; Catecholamines; Debrisoquin; Double-Blind Method | 1993 |
Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Brief Psychiatric Rating Scale; Female; Fluphenaz | 1995 |
Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Erythrocytes; Female; Haloperidol; Homo | 1995 |
Catatonia: short-term response to lorazepam and dopaminergic metabolism.
Topics: Acute Disease; Adult; Anti-Anxiety Agents; Anxiety; Catatonia; Depressive Disorder; Dopamine; Dyskin | 1995 |
Predicting haloperidol treatment response in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Haloperidol; Homovanillic Acid; Humans; Male; Methoxyh | 1996 |
A study of the potential confounding effects of diet, caffeine, nicotine and lorazepam on the stability of plasma and urinary homovanillic acid levels in patients with schizophrenia.
Topics: Adult; Caffeine; Central Nervous System Stimulants; Diet; Drug Interactions; GABA Modulators; Homova | 1996 |
Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: a within-subject comparison with haloperidol.
Topics: Aged; Analysis of Variance; Antipsychotic Agents; Clozapine; Haloperidol; Homovanillic Acid; Humans; | 1997 |
Differential effect of haloperidol and clozapine on plasma homovanillic acid in elderly schizophrenic patients with or without tardive dyskinesia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Clozapine; Dyskinesia, Drug-Induced; Female; Haloperi | 1998 |
Plasma 3-methoxy-4-hydroxyphenylglycol and homovanillic acid measurements in deficit and nondeficit forms of schizophrenia.
Topics: Aged; Female; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Middle Aged; Norepinephri | 1998 |
The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers.
Topics: Adult; Affect; Antipsychotic Agents; Behavior; Blood Pressure; Body Temperature; Brief Psychiatric R | 1998 |
Pretreatment plasma homovanillic acid in schizophrenia and schizoaffective disorder: the influence of demographic variables and the inpatient drug-free period.
Topics: Adult; Age of Onset; Brief Psychiatric Rating Scale; Female; Homovanillic Acid; Humans; Male; Psycho | 1998 |
Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol.
Topics: Adult; Antipsychotic Agents; Clozapine; Electroencephalography; Evoked Potentials, Auditory; Female; | 1999 |
Differential effects of mental stress on plasma homovanillic acid in schizophrenia and normal controls.
Topics: Adolescent; Adult; Homovanillic Acid; Humans; Male; Reference Values; Schizophrenia; Schizophrenic P | 1999 |
The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; M | 2001 |
Monoamine metabolite levels in cerebrospinal fluid of psychotic women treated with melperone or thiothixene.
Topics: Antipsychotic Agents; Butyrophenones; Clinical Trials as Topic; Double-Blind Method; Female; Glycols | 1977 |
Tardive dyskinesia: a clinical test of the supersensitivity hypothesis.
Topics: Adult; Aged; Clinical Trials as Topic; Cyclic AMP; Depression; Dyskinesia, Drug-Induced; Female; Hom | 1979 |
Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind crossover technique.
Topics: Aged; Chronic Disease; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Female; | 1976 |
Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients.
Topics: Adult; Aged; Chlorpromazine; Ethylene Glycols; Female; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1977 |
Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients.
Topics: Adult; Aged; Basal Ganglia Diseases; Clinical Trials as Topic; Clozapine; Dibenzazepines; Haloperido | 1975 |
Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administrat | 1992 |
Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.
Topics: Adult; Antipsychotic Agents; Clozapine; Dopamine; Double-Blind Method; Female; Fluphenazine; Homovan | 1992 |
Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited.
Topics: Acute Disease; Haloperidol; Homovanillic Acid; Humans; Placebos; Psychiatric Status Rating Scales; S | 1992 |
Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
Topics: Adult; Aged; Biomarkers; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Ind | 1992 |
Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients.
Topics: Adult; Brain; Depressive Disorder; Double-Blind Method; Female; Growth Hormone; Homovanillic Acid; H | 1991 |
Plasma homovanillic acid, serum anti-D1 and anti-D2 receptor activity, and psychopathology in chronic schizophrenia.
Topics: Antipsychotic Agents; Benzazepines; Chronic Disease; Haloperidol; Homovanillic Acid; Humans; Male; M | 1991 |
Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients.
Topics: Acute Disease; Adolescent; Adult; Antipsychotic Agents; Benzamides; Delayed-Action Preparations; Dou | 1990 |
Pharmacological effects of methylphenidate on plasma homovanillic acid and growth hormone.
Topics: Adult; Affective Disorders, Psychotic; Blood Pressure; Brain; Double-Blind Method; Female; Growth Ho | 1990 |
Cholecystokinin, dopamine and schizophrenia.
Topics: Adult; Cholecystokinin; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Male; Neurons; Sch | 1990 |
Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with schizophrenia.
Topics: Adult; Circadian Rhythm; Depression, Chemical; Dopamine; Female; Fluphenazine; Homovanillic Acid; Hu | 1990 |
Hemodialysis in the treatment of a group of schizophrenic patients.
Topics: Adult; Cholesterol, HDL; Clinical Trials as Topic; Double-Blind Method; Female; Follow-Up Studies; H | 1985 |
Clonidine treatment of schizophrenia: can we predict treatment response?
Topics: Adult; Clinical Trials as Topic; Clonidine; Growth Hormone; Homovanillic Acid; Humans; Hydroxyindole | 1989 |
Melperone in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Butyrophenones; Diazepam; Double-Blind Method; Drug Therapy, Combination; Homo | 1989 |
Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment.
Topics: Adolescent; Adult; Amino Acids; Biogenic Monoamines; Female; Glutamates; Glutamine; Homovanillic Aci | 1989 |
A.E. Bennett award paper. Experimental approaches to human stress research: assessment of neurobiological mechanisms of stress in volunteers and psychiatric patients.
Topics: Adrenocorticotropic Hormone; Adult; Arousal; beta-Endorphin; Blood Glucose; Clinical Trials as Topic | 1989 |
Fluphenazine treatment reduces CSF somatostatin in patients with schizophrenia: correlations with CSF HVA.
Topics: Adult; Brain; Clinical Trials as Topic; Female; Fluphenazine; Homovanillic Acid; Humans; Male; Schiz | 1989 |
Clozapine in China: a review and preview of US/PRC collaboration.
Topics: Adult; China; Chlorpromazine; Clozapine; Dibenzazepines; Double-Blind Method; Female; Homovanillic A | 1989 |
Pharmacodynamics and pharmacokinetics of haloperidol and reduced haloperidol in schizophrenic patients.
Topics: Adult; Biological Availability; Brain; Chronic Disease; Haloperidol; Homovanillic Acid; Humans; Male | 1989 |
Metabolic stress effects in normal volunteers and schizophrenic patients.
Topics: Adrenocorticotropic Hormone; Deoxyglucose; Endorphins; Female; Homovanillic Acid; Humans; Hydrocorti | 1988 |
Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain; Catecholamines; Clinical Trials as Topic; Double-Bli | 1988 |
Urine and plasma levels of dopamine metabolites in response to apomorphine and neuroleptics in schizophrenics.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Apomorphine; Chronic Disease; Clinical Trials as Topic; Diben | 1988 |
Clinical and biochemical effects of verapamil administration to schizophrenic patients.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Emotions; Female; Homovanillic Acid; Hostility | 1987 |
Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment.
Topics: Adult; Dopamine; Female; Fluphenazine; Homovanillic Acid; Humans; Male; Middle Aged; Psychiatric Sta | 1986 |
Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzazepi | 1974 |
The effect of chlorpromazine on homovanillic acid levels in cerebrospinal fluid of schizophrenic patients.
Topics: Adult; Chlorpromazine; Dose-Response Relationship, Drug; Female; Homovanillic Acid; Humans; Male; Ma | 1974 |
298 other studies available for homovanillic acid and Schizophrenia
| Article | Year |
|---|---|
[Variations in fecal microbiota of first episode schizophrenia associated with clinical assessment and serum metabolomics].
Topics: Antipsychotic Agents; Feces; Homovanillic Acid; Humans; Metabolomics; Methionine; Microbiota; Prolin | 2022 |
Plasma levels of 3-methoxy-4-hydroxyphenylglycol levels, number of hospitalization and cognitive function predicts the cognitive effect of atypical antipsychotic monotherapy in patients with acute schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Cognition; Female; Homovanillic Acid | 2020 |
Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis.
Topics: Adult; Aged; Antipsychotic Agents; Dopamine; Female; Homovanillic Acid; Humans; Male; Methoxyhydroxy | 2020 |
Plasma levels of dopamine metabolite correlate with mismatch negativity in patients with schizophrenia.
Topics: Adult; Dopamine; Electroencephalography; Evoked Potentials; Evoked Potentials, Auditory; Female; Hom | 2020 |
Preventive role of regular low-intensity exercise during adolescence in schizophrenia model mice with abnormal behaviors.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Behavior, Animal; Disease Models, Animal; Dopa | 2021 |
Reduction of dopamine and glycogen synthase kinase-3 signaling in rat striatum after continuous administration of haloperidol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Corpus Striatum; Dopamine; Glycogen S | 2021 |
Dynamic changes in near-infrared spectroscopy (NIRS) findings in first-episode schizophrenia: a case report.
Topics: Acute Disease; Adolescent; Antipsychotic Agents; Biomarkers; Blood Volume; Cerebrovascular Circulati | 2017 |
No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals.
Topics: Adolescent; Adult; Biogenic Monoamines; Biomarkers; Female; Homovanillic Acid; Humans; Hydroxyindole | 2018 |
Influence of -141C Ins/Del Polymorphism in DRD2 Gene on Clinical Symptoms and Plasma Homovanillic Acid Levels in the Treatment of Schizophrenia With Aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Homovanillic Acid; Humans; INDEL Mutation; Male; | 2015 |
Associations between five-factor model of the Positive and Negative Syndrome Scale and plasma levels of monoamine metabolite in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Humans | 2015 |
Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy.
Topics: Adult; Antipsychotic Agents; Biomarkers; Brain-Derived Neurotrophic Factor; Case-Control Studies; Ch | 2017 |
Genetic and Functional Study of L-Type Amino Acid Transporter 1 in Schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Cells, Cultured; Female; Fibroblasts; Genetic | 2016 |
Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Biomarkers; Brain-Derived Neurotrophic Factor; Cognition; | 2017 |
Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Brain Diseases; Chromatography, High Press | 2009 |
Plasma homovanillic acid differences in clinical subgroups of first episode schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Dopamine; Female; Follow-Up Studies; Homovanillic Acid; Humans; Male; P | 2009 |
GABA and homovanillic acid in the plasma of Schizophrenic and bipolar I patients.
Topics: Adolescent; Adult; Biomarkers; Bipolar Disorder; Dopamine; Female; gamma-Aminobutyric Acid; Homovani | 2010 |
Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Cognition Disorders; Fem | 2009 |
Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain-Derived Neurotrophic F | 2010 |
Comparison of brain N-acetylaspartate levels and serum brain-derived neurotrophic factor (BDNF) levels between patients with first-episode schizophrenia psychosis and healthy controls.
Topics: Adolescent; Adult; Aspartic Acid; Basal Ganglia; Brain Chemistry; Brain-Derived Neurotrophic Factor; | 2011 |
Early death and CSF monoamine metabolites in schizophrenia spectrum psychosis.
Topics: Adult; Age Factors; Cause of Death; Cerebrospinal Fluid; Female; Follow-Up Studies; Homovanillic Aci | 2011 |
Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF.
Topics: Adolescent; Adult; Biomarkers; Dibenzothiazepines; Female; Homovanillic Acid; Humans; Hydroxyindolea | 2010 |
Variability of plasma homovanillic acid over 13 months in patients with schizophrenia; relationship with the clinical response and the Wisconsin card sort test.
Topics: Adult; Antipsychotic Agents; Female; Homovanillic Acid; Humans; Male; Neuropsychological Tests; Psyc | 2011 |
α7 neuronal nicotinic receptor agonist (TC-7020) reverses increased striatal dopamine release during acoustic PPI testing in a transgenic mouse model of schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acoustic Stimulation; Animals; Chromatography, High Pressure Liquid; | 2012 |
Long-term pharmacoclinical follow-up in schizophrenic patients treated with risperidone. Plasma and red blood cell concentrations of risperidone and its 9-hydroxymetabolite and their relationship to whole blood serotonin and tryptophan, plasma homovanilli
Topics: Adult; Aged; Analysis of Variance; Biomarkers; Female; Follow-Up Studies; Homovanillic Acid; Humans; | 2002 |
Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia.
Topics: Adult; Antipsychotic Agents; Biogenic Monoamines; Dopamine; Female; Homovanillic Acid; Humans; Hydro | 2002 |
Effects of acute metabolic stress on the peripheral vasopressinergic system in schizophrenia.
Topics: Adrenocorticotropic Hormone; Adult; Behavior; Female; Homovanillic Acid; Humans; Hydrocortisone; Hyd | 2003 |
Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Caffeine; Catecholamines; Cen | 2005 |
Monoaminergic dysregulation in glutathione-deficient mice: possible relevance to schizophrenia?
Topics: Amphetamine; Animals; Brain; Chromatography, High Pressure Liquid; Dopamine; Glutathione; Hallucinog | 2005 |
Diurnal variation in plasma homovanillic acid in patients with schizophrenia and healthy controls.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Circadian Rhythm; Female; Homovanillic Acid; Huma | 2006 |
Fibroblast growth factor receptor signaling affects development and function of dopamine neurons - inhibition results in a schizophrenia-like syndrome in transgenic mice.
Topics: Animals; Cell Differentiation; Cell Enlargement; Disease Models, Animal; Dopamine; Dopamine Plasma M | 2006 |
Evidence that brain tissue volumes are associated with HVA reactivity to metabolic stress in schizophrenia.
Topics: Adolescent; Adult; Deoxyglucose; Female; Homovanillic Acid; Humans; Image Processing, Computer-Assis | 2006 |
Inter- and intra-individual variability in the levels of plasma homovanillic acid in schizophrenic patients.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Female; Homovanillic Acid; Humans; Individuality; | 2007 |
Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Drug Interactions; Female; Homovanillic Acid; Humans; | 2007 |
Plasma homovanillic acid levels in schizophrenic patients: correlation with negative symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Depression; Dopamine; Female; Hallucinations; Haloperidol; | 2007 |
Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls.
Topics: Adrenocorticotropic Hormone; Adult; Control Groups; Cross-Over Studies; Deoxyglucose; Dopamine; Doub | 2008 |
[The probenecid test and its application to research in schizophrenia].
Topics: Biogenic Amines; Brain; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Methoxyhydroxyphenylgly | 1984 |
[Changes in the CSF levels of monoamine metabolites in 102 chronic schizophrenic patients following probenecid before and after neuroleptic medication].
Topics: Adult; Antipsychotic Agents; Biogenic Amines; Chronic Disease; Female; Homovanillic Acid; Humans; Hy | 1984 |
The Genain Quadruplets 25 years later: a diagnostic and biochemical followup.
Topics: 3,4-Dihydroxyphenylacetic Acid; Cyclic AMP; Dopamine beta-Hydroxylase; Environment; Female; Follow-U | 1984 |
[State of the adrenergic and cholinergic systems of schizophrenic patients during the process of psychopharmacotherapy].
Topics: Acetylcholine; Acetylcholinesterase; Adult; Antipsychotic Agents; Catecholamines; Dihydroxyphenylala | 1980 |
Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Female; Haloperidol; Homovanillic Acid; Humans; Male; P | 1981 |
"Tolerance" to neuroleptic-induced CSF HVA rise in schizophrenic patients in relation to clinical response.
Topics: Antipsychotic Agents; Drug Tolerance; Homovanillic Acid; Humans; Phenylacetates; Schizophrenia | 1982 |
The dopamine hypothesis: an overview of studies with schizophrenic patients.
Topics: Adenylyl Cyclases; Brain; Catechol O-Methyltransferase; Dextroamphetamine; Dopa Decarboxylase; Dopam | 1982 |
Effect of chronic amphetamine administration on dopaminergic systems in the vervet brain: relationship to findings in the brains of schizophrenics.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamines; Animals; Brain; Chlorocebus aethiops; Dopa Decarboxyla | 1983 |
Neurochemical studies on tardive dyskinesia. I. Urinary homovanillic acid and plasma prolactin.
Topics: Aged; Antipsychotic Agents; Dopamine; Dyskinesia, Drug-Induced; Homovanillic Acid; Humans; Male; Mid | 1983 |
Dopamine-beta-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy.
Topics: Adolescent; Adult; Aged; Animals; Antipsychotic Agents; Atrophy; Brain; Dopamine; Dopamine beta-Hydr | 1983 |
Urinary acid metabolites of biogenic amines in schizophrenic patients.
Topics: Biogenic Amines; Blood Platelets; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Indoleacetic | 1980 |
CSF monoamine metabolites in child and adult psychiatric patients. A developmental perspective.
Topics: Adolescent; Adult; Age Factors; Aged; Autistic Disorder; Bipolar Disorder; Child; Child, Preschool; | 1980 |
Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients.
Topics: Adolescent; Adult; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Metho | 1980 |
Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs.
Topics: Antipsychotic Agents; Chlorpromazine; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; | 1980 |
Noradrenergic overactivity in chronic schizophrenia: evidence based on cerebrospinal fluid noradrenaline and cyclic nucleotide concentrations.
Topics: Adult; Chronic Disease; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Middle Ag | 1980 |
Relationship between estimated premorbid adjustment and CSF homovanillic acid and 5-hydroxyindoleacetic acid levels.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Aged; Female; Homovanillic Acid; Humans; Hydroxyi | 1981 |
[Catecholamine and indoleamine metabolism in groups of patients with paranoid and simple forms of schizophrenia].
Topics: Adult; Biogenic Amines; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Mal | 1981 |
[Changes in the levels of adrenergic and serotoninergic indices in patients with depressive states].
Topics: Adolescent; Adult; Biogenic Amines; Depression; Dihydroxyphenylalanine; Dopamine; Epinephrine; Homov | 1981 |
Reduced lumbar CSF somatostatin levels in Alzheimer's disease.
Topics: Aged; Alcohol Amnestic Disorder; Alzheimer Disease; Dementia; Female; Homovanillic Acid; Humans; Hyd | 1982 |
Relationship between cerebrospinal fluid amine metabolites, neuroendocrine findings and personality dimensions (Marke-Nyman scale factors) in psychiatric patients.
Topics: Alcoholism; Bipolar Disorder; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; | 1983 |
Amine metabolites and neuroendocrine responses related to depression and suicide.
Topics: Alcoholism; Depression; Depressive Disorder; Dexamethasone; Female; Homovanillic Acid; Humans; Hydro | 1983 |
The effect of dexamethasone on cerebrospinal fluid monoamine metabolites and cortisol in psychiatric patients.
Topics: Adult; Aged; Alcoholism; Bipolar Disorder; Depressive Disorder; Dexamethasone; Female; Homovanillic | 1983 |
Gamma-hydroxybutyrate in the treatment of schizophrenia.
Topics: Adult; Double-Blind Method; Homovanillic Acid; Humans; Hydroxybutyrates; Hydroxyindoleacetic Acid; M | 1983 |
Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid of chronic therapy-resistant schizophrenics before and after hemodialysis therapy.
Topics: Adult; Chromatography, High Pressure Liquid; Double-Blind Method; Female; Homovanillic Acid; Humans; | 1983 |
Smooth pursuit eye movements, clinical symptoms, CSF metabolites, and skin conductance habituation in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Eye Movements; Female; Galvanic Skin Response; Habitua | 1983 |
Cerebrospinal fluid biochemical examinations: do they reflect clinical or biological differences?
Topics: Adult; Aged; Alcoholism; Bipolar Disorder; Calcium; Depressive Disorder; Dexamethasone; Female; Homo | 1983 |
Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers.
Topics: Adult; Age Factors; Cerebral Ventriculography; Female; Homovanillic Acid; Humans; Hydroxyindoleaceti | 1983 |
Reliability of norepinephrine and major monoamine metabolite measurements in CSF of schizophrenic patients.
Topics: Adult; Chronic Disease; Female; Glycols; Homovanillic Acid; Hospitalization; Humans; Hydroxyindoleac | 1983 |
Measurement of 3-methoxy-4-hydroxyphenylacetic acid (HVA) in plasma by high-performance liquid chromatography with electrochemical detector (HPLC-EC).
Topics: Animals; Antipsychotic Agents; Chromatography, High Pressure Liquid; Electrochemistry; Female; Homov | 1983 |
Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients.
Topics: Adolescent; Adult; Cerebrospinal Fluid Proteins; Chlorpromazine; Dopamine Antagonists; Female; Homov | 1984 |
Elevated cerebrospinal fluid noradrenaline in tardive dyskinesia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Antipsychotic Agents; Dyskinesia, Drug-Induced; Homovan | 1984 |
Effect of propranolol on monoamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia.
Topics: Adult; Chromatography, High Pressure Liquid; Double-Blind Method; Drug Evaluation; Female; Homovanil | 1984 |
Bilateral skin conductance activity, clinical symptoms and CSF monoamine metabolite levels in unmedicated schizophrenics, differing in rate of habituation.
Topics: Adult; Biogenic Amines; Female; Galvanic Skin Response; Habituation, Psychophysiologic; Homovanillic | 1984 |
Seasonal variations of human lumbar CSF neurotransmitter metabolite concentrations.
Topics: Adult; Alzheimer Disease; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxy | 1984 |
CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls.
Topics: Adolescent; Adult; Age Factors; Aged; Bipolar Disorder; Calcium; Choline; Depressive Disorder; Femal | 1984 |
Short- and long-term effects of GABA and dopamine neurons during treatment with sulpiride.
Topics: Cyclic AMP; Cyclic GMP; Dopamine; gamma-Aminobutyric Acid; Homovanillic Acid; Humans; Neurons; Prola | 1980 |
Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients.
Topics: Adult; Dopamine; Female; Fluphenazine; Homovanillic Acid; Humans; Male; Phenylacetates; Schizophreni | 1984 |
Seasonal variation in human central dopamine activity.
Topics: Adult; Blinking; Brain Chemistry; Dopamine; Female; Homovanillic Acid; Humans; Hypothalamus; Male; M | 1984 |
Plasma catecholamine metabolites and early response to haloperidol.
Topics: Acute Disease; Adolescent; Adult; Female; Glycols; Haloperidol; Homovanillic Acid; Hospitalization; | 1984 |
[Various features of dopamine metabolism in schizophrenia].
Topics: Dihydroxyphenylalanine; Dopamine; Epinephrine; Homovanillic Acid; Humans; Norepinephrine; Schizophre | 1981 |
[Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
Topics: Adult; Dose-Response Relationship, Drug; Female; gamma-Aminobutyric Acid; Haloperidol; Homovanillic | 1982 |
Determination of p-hydroxyphenylacetic acid in cerebrospinal fluid by high-performance liquid chromatography with electrochemical detection.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adolescent; Adult; Aged; Child; Child, Preschool; Chromatography, Ge | 1982 |
Conditioned dopaminergic activity.
Topics: Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Conditioning, Classical; Cues; Dextroamphet | 1982 |
[Biochemical analysis of dopaminergic nerve terminals of post-mortem brain from schizophrenic patients (author's transl)].
Topics: Adult; Aged; Brain Chemistry; Dopamine; Female; Homovanillic Acid; Humans; Male; Middle Aged; Nerve | 1981 |
CSF monoamine metabolites in depression and schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Depression; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mal | 1980 |
Schizophrenia: gender, family risk, and plasma homovanillic acid.
Topics: Adolescent; Adult; Family; Female; Haloperidol; Homovanillic Acid; Humans; Male; Risk Factors; Schiz | 1995 |
An association between low levels of 5-HIAA and HVA in cerebrospinal fluid and early mortality in a diagnostically mixed psychiatric sample.
Topics: Adult; Aged; Cause of Death; Depressive Disorder; Follow-Up Studies; Homovanillic Acid; Hospital Rec | 1993 |
Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
Topics: Adult; Chromogranin A; Chromogranins; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Ac | 1994 |
Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function.
Topics: Adult; Cerebral Cortex; Cognition Disorders; Discrimination Learning; Dopamine; Homovanillic Acid; H | 1994 |
Effectiveness of concomitant setiptiline maleate (Tecipul) on negative symptoms of schizophrenia.
Topics: Adult; Biogenic Monoamines; Chronic Disease; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1994 |
CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.
Topics: Adult; Female; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydrox | 1994 |
Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Chromatography, High Pressure Liquid; | 1994 |
Clozapine therapy and increases in homovanillic acid.
Topics: Chromatography, High Pressure Liquid; Clozapine; Dopamine; Homovanillic Acid; Humans; Hydroxyindolea | 1995 |
Behavioral vs biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.
Topics: Adult; Age of Onset; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Logistic Mode | 1995 |
Decreased DOPAC in the anterior cingulate cortex of individuals with schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Age Factors; Aged; Antipsychotic Agents; Autopsy; Female; Gas | 1995 |
Schizophrenic patients with deficit syndrome have higher plasma homovanillic acid concentrations and ventricular enlargement.
Topics: Adult; Cerebral Ventricles; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Humans; | 1995 |
CSF 5-HIAA and atmospheric pressure: failure to replicate.
Topics: Atmospheric Pressure; Body Height; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacet | 1993 |
Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment.
Topics: Adult; Dopamine; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Psychiatric | 1993 |
Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics.
Topics: Adult; Antipsychotic Agents; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Meth | 1993 |
Are monoamine metabolites in cerebrospinal fluid worth measuring?
Topics: Animals; Brain; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mental Disorders; Met | 1993 |
Low cerebrospinal fluid homovanillic acid-5-hydroxyindoleacetic acid ratio predicts clozapine efficacy: a replication.
Topics: Clozapine; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Prospective Studies; Psychiatric Sta | 1993 |
Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Chronic Disease; Female; Follow-Up Studies; H | 1995 |
Low concentrations of serum tyrosine in neuroleptic-free schizophrenics with an early onset.
Topics: Adult; Age of Onset; Brain; Chromatography, High Pressure Liquid; Homovanillic Acid; Humans; Male; M | 1995 |
Assessment of the central dopaminergic index of plasma HVA in schizophrenia.
Topics: Brain; Debrisoquin; Dopamine; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Neurons; | 1995 |
Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function.
Topics: Adult; alpha-Methyltyrosine; Antipsychotic Agents; Basal Ganglia Diseases; Dopamine; Drug Resistance | 1994 |
Monoamine activity reflected in urine of young patients with obsessive compulsive disorder, psychosis with and without reality distortion and healthy subjects: an explorative analysis.
Topics: Adolescent; Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Creatinine; Dopamine; Epine | 1994 |
Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Arousal; Chronic Disease; Homovanillic Acid; Hospitalization; Humans; L | 1994 |
Plasma homovanillic acid levels in first-episode schizophrenia. Psychopathology and treatment response.
Topics: Adult; Antipsychotic Agents; Confidence Intervals; Female; Homovanillic Acid; Humans; Male; Psychiat | 1994 |
A comparison of plasma homovanillic acid in the deficit and nondeficit subtypes of schizophrenia.
Topics: Adult; Arousal; Female; Homovanillic Acid; Humans; Male; Psychiatric Status Rating Scales; Schizophr | 1994 |
Disposition of clozapine and desmethylclozapine in schizophrenic patients.
Topics: Adult; Chronic Disease; Clozapine; Dextromethorphan; Half-Life; Homovanillic Acid; Humans; Male; Met | 1994 |
Auditory sensory gating, hippocampal volume, and catecholamine metabolism in schizophrenics and their siblings.
Topics: Acoustic Stimulation; Adult; Amygdala; Arousal; Attention; Catecholamines; Chronic Disease; Dopamine | 1994 |
B-HT 920, a dopamine D2 agonist, in the treatment of negative symptoms of chronic schizophrenia.
Topics: Arousal; Azepines; Brain; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induce | 1993 |
Studies on neurochemical heterogeneity in healthy parents of schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Female; Homovanillic Acid; Humans; Male; Middle Aged; Norepinephr | 1993 |
Homovanillic acid in the cerebrospinal fluid: patterns of response after four weeks of neuroleptic treatment.
Topics: Adult; Age of Onset; Antipsychotic Agents; Brain; Dopamine; Drug Tolerance; Female; Glutamates; Homo | 1993 |
Psychotic patients with increased plasma HVA and MHPG or increased HVA alone.
Topics: Adult; Arousal; Female; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Psychiatric Sta | 1993 |
An association between increased concentrations of cerebrospinal fluid dopamine sulfate and higher negative symptom scores in patients with schizophrenia and schizoaffective disorder.
Topics: Chronic Disease; Dopamine; Homovanillic Acid; Humans; Psychiatric Status Rating Scales; Psychotic Di | 1993 |
Influence of renal clearance on peripheral homovanillic acid measurements in healthy subjects and schizophrenic patients.
Topics: Adult; Brain; Creatinine; Dopamine; Glomerular Filtration Rate; Homovanillic Acid; Humans; Male; Met | 1993 |
Effects of single dose haloperidol administration on plasma homovanillic acid levels in normal subjects.
Topics: Adolescent; Adult; Circadian Rhythm; Dopamine; Haloperidol; Homovanillic Acid; Humans; Male; Schizop | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Haloperidol response and plasma catecholamines and their metabolites.
Topics: Adult; Catecholamines; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Longitudinal Studie | 1993 |
Serum homovanillic acid levels in schizophrenic patients and normal control subjects.
Topics: Adult; Homovanillic Acid; Humans; Male; Psychiatric Status Rating Scales; Reference Values; Schizoph | 1993 |
On the value of measuring dopamine, norepinephrine and their metabolites in schizophrenia.
Topics: Dopamine; Homovanillic Acid; Humans; Norepinephrine; Schizophrenia | 1993 |
Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia.
Topics: Adult; Clozapine; Dopamine; Female; Homovanillic Acid; Humans; Male; Norepinephrine; Receptors, Adre | 1993 |
Effects of haloperidol decanoate on plasma homovanillic acid in chronic schizophrenic patients.
Topics: Adult; Brain; Chronic Disease; Delayed-Action Preparations; Female; Haloperidol; Homovanillic Acid; | 1993 |
Plasma prolactin and plasma homovanillic acid: predictors of clinical response in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Haloperidol; Homovanillic Acid; Humans; Male; Prola | 1995 |
The relationship between urine excretion and biogenic amines and their metabolites in cerebrospinal fluid of schizophrenic patients.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Biogenic Amines; Chronic Disease; Drinking; Female; Histamine | 1996 |
Exaggerated responsivity of brain dopaminergic system activity in schizophrenia: a preliminary finding of increased variance of plasma homovanillic acid level in a chronic patient.
Topics: Adult; Brain; Chronic Disease; Dopamine; Female; Homovanillic Acid; Humans; Hydrocortisone; Hydroxyi | 1996 |
Dopamine turnover in schizophrenia before and after haloperidol withdrawal. CSF, plasma, and urine studies.
Topics: Adult; Dopamine; Haloperidol; Homovanillic Acid; Humans; Male; Schizophrenia | 1996 |
Impact of neuroleptic medications on continuous performance test measures in schizophrenia.
Topics: Adult; Antipsychotic Agents; Attention; Female; Homovanillic Acid; Humans; Male; Middle Aged; Schizo | 1996 |
Tyrosine transport as an indicator of cell membrane dysfunction in schizophrenia.
Topics: Amino Acids; Biological Transport; Biopsy; Carbon Radioisotopes; Female; Fibroblasts; Homovanillic A | 1996 |
Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
Topics: Adult; Aged; Antipsychotic Agents; Depression; Dopamine D2 Receptor Antagonists; Dose-Response Relat | 1996 |
Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance.
Topics: Antipsychotic Agents; Female; Homovanillic Acid; Humans; Male; Prolactin; Psychiatric Status Rating | 1997 |
Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations.
Topics: Adult; Aged; Brain; Dopamine; Homovanillic Acid; Humans; Male; Middle Aged; Psychiatric Status Ratin | 1997 |
Association of DNA polymorphism in the first intron of the tyrosine hydroxylase gene with disturbances of the catecholaminergic system in schizophrenia.
Topics: Adult; Analysis of Variance; Case-Control Studies; Catecholamines; Chi-Square Distribution; Female; | 1997 |
A biomodal distribution of plasma HVA/MHPG in the psychoses.
Topics: Adult; Female; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Psychotic Disorders; Sch | 1997 |
Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine.
Topics: Adult; Antipsychotic Agents; Clozapine; Homovanillic Acid; Humans; Male; Schizophrenia; Treatment Ou | 1997 |
Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia.
Topics: Adult; Aged; Amantadine; Chronic Disease; Dopamine Agents; Dose-Response Relationship, Drug; Drug Ad | 1997 |
Improvement of schizophrenic symptoms and changes in plasma HVA concentrations, plasma anti-D2 and anti-5-HT2 receptor activities with clozapine.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Clozapine; Dopamine; Homovanillic Acid; Humans; Male; | 1996 |
Evolution of plasma homovanillic acid (HVA) in chronic schizophrenic patients treated with haloperidol.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Dopamine Antagonists; Dose-Response Relationship, | 1998 |
Failure to replicate an association between a rare allele of a tyrosine hydroxylase gene microsatellite and schizophrenia.
Topics: Alleles; Gene Expression Regulation, Enzymologic; Gene Frequency; Homovanillic Acid; Humans; Hydroxy | 1998 |
Neurochemical variables in schizophrenic patients during switching from neuroleptics to clozapine.
Topics: Adolescent; Adult; Antipsychotic Agents; Chlorpromazine; Clozapine; Homovanillic Acid; Humans; Hydro | 1998 |
CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid | 1998 |
Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia.
Topics: Adult; Antipsychotic Agents; Biomarkers; Bipolar Disorder; Catecholamines; Homovanillic Acid; Humans | 1999 |
Genetic antecedents of dopamine dysfunction in schizophrenia.
Topics: Adult; Chromatography, High Pressure Liquid; Dopamine; Female; Homovanillic Acid; Humans; Male; Midd | 1999 |
[Study on dopamine metabolite in cerebrospinal fluid of schizophrenics and epilepsics].
Topics: Adult; Dopamine; Epilepsy; Female; Homovanillic Acid; Humans; Male; Middle Aged; Schizophrenia | 1998 |
Plasma homovanillic acid in the prodromal phase of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Biomarkers; Case-Control Studies; Dopamine; Homovanillic Acid; Hum | 2000 |
Neonatal lesions of the left entorhinal cortex affect dopamine metabolism in the rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amygdala; Animals; Animals, Newborn; Brain; Caudate Nucleus; Disease | 2000 |
Season of birth variations in dimensions of functioning evaluated by the diagnostic interview for borderline patients.
Topics: Anxiety Disorders; Biogenic Monoamines; Birth Certificates; Borderline Personality Disorder; Homovan | 2000 |
Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics.
Topics: Adult; Antipsychotic Agents; Dopamine; Enzyme-Linked Immunosorbent Assay; Haloperidol; Homovanillic | 2000 |
Schizophrenia and plasma homovanillic acid in response to mental stress: methodological considerations.
Topics: Circadian Rhythm; Homovanillic Acid; Humans; Schizophrenia; Stress, Psychological | 2000 |
Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Biomarkers; Cerebral Ventricles; Child; Family; Homov | 2000 |
Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Central Nervous System Stimulants; Corpus Stri | 2001 |
Relationship of symptomatology, gender, and antipsychotic drug treatment with plasma homovanillic acid in schizophrenia.
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Female; Homovanillic Acid; Humans; Male; Middle Aged; S | 2001 |
Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adolescent; Adrenocorticotropic Hormone; Adult; Bipolar Disorder; Ca | 2002 |
Transmitter precursors and metabolites in human ventricular cerebrospinal fluid.
Topics: Cerebral Ventricles; Frontal Lobe; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Neurotic Dis | 1976 |
Clinical assessment of dopamine receptor blockade.
Topics: Antipsychotic Agents; Homovanillic Acid; Humans; Methoxyhydroxyphenylglycol; Prolactin; Receptors, D | 1978 |
Antipsychotic drug action in schizophrenic patients: effect on cortical dopamine metabolism after long-term treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Antipsychotic Agents; Brain; Cerebral Cortex; Dopamine; Homovanillic | 1979 |
Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor.
Topics: Adult; Chronic Disease; Cyclic AMP; Cyclic GMP; Cyproheptadine; Dyskinesia, Drug-Induced; Female; Ho | 1979 |
The dopamine hypothesis of schizophrenia revisited.
Topics: Antipsychotic Agents; Cerebral Cortex; Corpus Striatum; Dopamine; Dopamine beta-Hydroxylase; gamma-A | 1979 |
Dopamine and schizophrenia.
Topics: Animals; Chlorpromazine; Corpus Striatum; Dopamine; Dopamine Antagonists; Fluphenazine; Homovanillic | 1976 |
Dopamine and schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Dopamine; Homovanillic Acid; Humans; Rats; | 1976 |
Dopamine and schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Corpus Striatum; Drug Evaluation; Hom | 1977 |
Brain biochemistry in schizophrenia.
Topics: Brain; Dopamine; Glutamate Decarboxylase; Homovanillic Acid; Humans; Schizophrenia | 1978 |
Neuroleptic drugs and the dopamine hypothesis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dopamine; Homovanillic Acid; Humans; Limbi | 1979 |
Relationships between clinical and biochemical effects of melperone and thiothixene in psychotic women.
Topics: Butyrophenones; Diazepam; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Methoxyhydrox | 1979 |
Thiethylperazine; clinical antipsychotic efficacy and correlation with potency in predictive systems.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Corpus Striatum; Dopamine; Dopamine Anta | 1978 |
Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment.
Topics: Biogenic Amines; Electroconvulsive Therapy; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindol | 1979 |
Interactions between central monoaminergic systems: dopamine-serotonin.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Depression; Dopamine; Dyskinesia, Drug-Induced; Female; H | 1979 |
Cerebrospinal fluid cyclic AMP and acid monoamine metabolites following probenecid: studies in psychiatric patients.
Topics: Adolescent; Adult; Aged; Biogenic Amines; Chlorpromazine; Cyclic AMP; Depression; Female; Homovanill | 1979 |
Effect of probenecid on the concentration of the lumbar cerebrospinal fluid acidic metabolites of tyramine, octopamine, dopamine and norepinephrine.
Topics: Dopamine; Female; Gas Chromatography-Mass Spectrometry; Homovanillic Acid; Humans; Male; Norepinephr | 1977 |
Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology.
Topics: Adolescent; Adult; Child; Dopamine; Epilepsy, Temporal Lobe; Homovanillic Acid; Humans; Hydroxyindol | 1979 |
Monoamine metabolite levels in cerebrospinal fluid and brain atrophy in lobotomized schizophrenic patients.
Topics: Atrophy; Brain Diseases; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; | 1979 |
Monoamines and monoamine metabolites in brains from demented schizophrenics.
Topics: Brain; Brain Chemistry; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; | 1979 |
Dopamine and homovanillic acid concentrations in the post-mortem brain in schizophrenia [proceedings].
Topics: Brain; Caudate Nucleus; Dopamine; Homovanillic Acid; Humans; Nucleus Accumbens; Phenylacetates; Puta | 1979 |
Pathophysiological studies on schizophrenia with special reference to homovanillic acid concentration in cerebrospin fluid.
Topics: Adolescent; Adult; Female; Haloperidol; Homovanillic Acid; Humans; Male; Phenylacetates; Schizophren | 1979 |
Lithium: clinical effects and cerebrospinal fluid acid monoamine metabolites.
Topics: Adult; Affective Symptoms; Aged; Biogenic Amines; Bipolar Disorder; Depression; Electroencephalograp | 1977 |
MAO activity, csf amine metabolites, and drug-free improvement in schizophrenia.
Topics: Adolescent; Adult; Blood Platelets; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mal | 1978 |
CSF acid monoamine metabolites in psychotic syndromes: what might they signify?
Topics: Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Phenylacetates; Prognosis; Psychotic Disorders; | 1978 |
Effect of baclofen on cerebrospinal-fluid levels of 5-hydroxyindoleacetic acid and homovanillic acid.
Topics: Adult; Aminobutyrates; Baclofen; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; | 1977 |
The significance of dopamine for the mode of action of neuroleptics and the pathogenesis of schizophrenia.
Topics: Dopamine; Homovanillic Acid; Humans; Probenecid; Schizophrenia; Tranquilizing Agents | 1977 |
Nonstriatal dopaminergic neurons: Section XI. Dopaminergic neurons and mental diseases: Introduction: dopaminergic neurons and mental diseases.
Topics: Apomorphine; Bromocriptine; Catecholamines; Depression; Dopamine; Homovanillic Acid; Humans; Levodop | 1977 |
The Parkinsonian syndrome and its dopamine correlates.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Dopamine; Extrapyramidal Tracts; Female; Homovanillic A | 1977 |
CSF amine metabolites, clinical symptoms, and body movement in psychiatric patients.
Topics: Adult; Anger; Anxiety; Arousal; Brain; Depression; Female; Homovanillic Acid; Humans; Hydroxyindolea | 1976 |
CSF acid monoamine metabolities as a possible reflection of central MAO activity in chronic schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Chronic Disease; Female; Homovanillic Acid; Huma | 1976 |
Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol.
Topics: Adult; Female; Hallucinations; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mal | 1976 |
Precursors and metabolites of 5-hydroxytryptamine and dopamine in the ventricular cerebrospinal fluid of psychiatric patients.
Topics: Adult; Aged; Anxiety Disorders; Brain Diseases; Cerebral Ventricles; Depression; Female; Homovanilli | 1976 |
[Differences in serotonin and dopamine metabolism in psychopathy and sluggish schizophrenia].
Topics: Adult; Antisocial Personality Disorder; Dopamine; Homovanillic Acid; Humans; Hydroxyindoleacetic Aci | 1976 |
Thioridazine: central dopamine turnover and clinical effects of antipsychotic drugs.
Topics: Adolescent; Adult; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Midd | 1975 |
Role of biogenic amines in certain pathological conditions.
Topics: Acute Disease; Adult; Aggression; Biogenic Amines; Bipolar Disorder; Chlorpromazine; Chronic Disease | 1975 |
Cerebrospinal fluid amine metabolites in acute schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Amines; Bipolar Disorder; Dopamine; Homovanillic Acid; Humans; Hyd | 1975 |
Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients.
Topics: Bipolar Disorder; Brain; Chlorpromazine; Dopamine; Homovanillic Acid; Humans; Schizophrenia; Thiorid | 1975 |
Central noradrenergic function in man: vanillylmandelic acid in CSF.
Topics: Acute Disease; Affective Symptoms; Bipolar Disorder; Depression; Homovanillic Acid; Humans; Hydroxyi | 1975 |
Cerebrospinal fluid amine metabolites in affective illness and schizophrenia: clinical and pharmacological studies.
Topics: Affective Symptoms; Amines; Depression; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Imipram | 1975 |
Relationship of plasma HVA and treatment response in a large series of patients with schizophrenia.
Topics: Antipsychotic Agents; Homovanillic Acid; Humans; Prolactin; Psychiatric Status Rating Scales; Schizo | 1992 |
Measurements of plasma homovanillic acid in schizophrenic patients.
Topics: Antipsychotic Agents; Homovanillic Acid; Humans; Schizophrenia | 1992 |
Studies on concentrations of NA and HVA and activity of DBH in the serum from schizophrenic patients, first-degree relatives and normal subjects.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Dopamine beta-Hydroxylase; Female; Ho | 1992 |
Electrodermal orienting response and central nervous system dopamine and serotonin activity in schizophrenia.
Topics: Acoustic Stimulation; Acute Disease; Adolescent; Adult; Brain; Dopamine; Galvanic Skin Response; Hom | 1992 |
Biogenic amine metabolites in plasma of drug-naive schizophrenic patients: associations with symptomatology.
Topics: Adult; Arousal; Chromatography, High Pressure Liquid; Homovanillic Acid; Hospitalization; Humans; Hy | 1992 |
Dopamine in schizophrenia.
Topics: Dopamine; Frontal Lobe; Homovanillic Acid; Humans; Limbic System; Schizophrenia; Schizophrenic Psych | 1992 |
Auditory sensory gating and catecholamine metabolism in schizophrenic and normal subjects.
Topics: Acoustic Stimulation; Adult; Arousal; Attention; Auditory Pathways; Cerebral Cortex; Electroencephal | 1992 |
Lithium in combination with perphenazine: effect on plasma monoamine metabolites.
Topics: Adult; Aged; Bipolar Disorder; Drug Therapy, Combination; Female; Homovanillic Acid; Humans; Lithium | 1992 |
Plasma homovanillic acid and other predictors of clozapine response.
Topics: Clozapine; Fluphenazine; Homovanillic Acid; Humans; Schizophrenia | 1992 |
Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia.
Topics: Adult; Aged; Apomorphine; Brain; Dyskinesia, Drug-Induced; Haloperidol; Homovanillic Acid; Humans; M | 1992 |
Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dopamine; Homovanillic Acid; Humans; Psychiatric Statu | 1991 |
Characteristics of psychotic inpatients with high or low HVA levels at admission.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Female; Gas Chromatography-Mass Spectrometry; Homovan | 1991 |
Plasma homovanillic acid and prognosis in schizophrenia.
Topics: Antipsychotic Agents; Follow-Up Studies; Homovanillic Acid; Hospitalization; Humans; Outcome and Pro | 1991 |
Norepinephrine in acute exacerbations of chronic schizophrenia. Negative symptoms revisited.
Topics: Acute Disease; Adult; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methox | 1990 |
Neuroleptic malignant syndrome: a study of CSF monoamine metabolism.
Topics: Adult; Biogenic Monoamines; Bipolar Disorder; Depressive Disorder; Female; Homovanillic Acid; Humans | 1990 |
Concentration gradients for HVA, 5-HIAA, ascorbic acid, and uric acid in cerebrospinal fluid.
Topics: Adult; Aged; Alcohol Amnestic Disorder; Ascorbic Acid; Brain; Dementia; Female; Homovanillic Acid; H | 1990 |
Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia.
Topics: Adult; Brain; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhyd | 1990 |
Effects of mianserin on negative symptoms in schizophrenia.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Brain; Chronic Disease; Drug Therapy, Combination | 1990 |
5-HIAA in cerebrospinal fluid and deficit schizophrenic characteristics.
Topics: Adult; Cognition; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Psychiatric Status Rating Sca | 1990 |
Relationship between abnormal brainstem auditory-evoked potentials and subnormal CSF levels of HVA and 5-HIAA in first-episode schizophrenic patients.
Topics: Adult; Brain Stem; Evoked Potentials, Auditory, Brain Stem; Female; Homovanillic Acid; Humans; Hydro | 1990 |
Intercorrelations among monoamine metabolite concentrations in human lumbar CSF are not due to a shared acid transport system.
Topics: Acid-Base Equilibrium; Administration, Oral; Blood-Brain Barrier; Depressive Disorder; Dose-Response | 1990 |
Lateral ventricle-brain ratio and balance between CSF HVA and 5-HIAA in schizophrenia.
Topics: Adult; Age Factors; Bipolar Disorder; Body Height; Body Weight; Brain; Brain Chemistry; Cerebral Ven | 1991 |
Regional brain glucose metabolism: correlations to biochemical measures and anxiety in patients with schizophrenia.
Topics: Adult; Anxiety; Arousal; Blood Glucose; Brain; Brain Mapping; Dominance, Cerebral; Energy Metabolism | 1991 |
CSF chromogranin A-like immunoreactivity in schizophrenia. Assessment of clinical and biochemical relationships.
Topics: Adult; Arousal; Atrophy; Brain; Chromogranin A; Chromogranins; Haloperidol; Homovanillic Acid; Human | 1991 |
[Plasma homovanillic acid level inpatients with deficit forms of schizophrenics].
Topics: Homovanillic Acid; Humans; Immunologic Deficiency Syndromes; Schizophrenia | 1991 |
Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
Topics: Administration, Oral; Adult; Chronic Disease; Depression, Chemical; Dopamine; Dopamine Antagonists; | 1991 |
Plasma free homovanillic acid (HVA) as a predictor of clinical response in acute psychosis.
Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Chromatography, High Pressure Liquid; Depressive | 1991 |
MMPI measures of impulsivity and depression correlate with CSF 5-HIAA and HVA in depression but not schizophrenia.
Topics: Adult; Depressive Disorder; Homovanillic Acid; Humans; Impulsive Behavior; Male; Middle Aged; MMPI; | 1991 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Psychotogenic drug use and neuroleptic response.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; Depressive Disorder; Haloperidol; Homovan | 1990 |
Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
Topics: Adult; Antipsychotic Agents; Drug Administration Schedule; Homovanillic Acid; Humans; Male; Schizoph | 1990 |
Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients.
Topics: Adult; Female; Haloperidol; Homovanillic Acid; Humans; Lithium; Male; Middle Aged; Neurotensin; Psyc | 1991 |
The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients.
Topics: Adult; Debrisoquin; Domperidone; Female; Fluphenazine; Homovanillic Acid; Humans; Male; Receptors, D | 1991 |
Plasma norepinephrine in chronic schizophrenia.
Topics: Adult; Chronic Disease; Female; Homovanillic Acid; Humans; Male; Norepinephrine; Posture; Psychiatri | 1990 |
Correlates of rapid neuroleptic response in male patients with schizophrenia.
Topics: Adult; Haloperidol; Homovanillic Acid; Humans; Male; Neuropsychological Tests; Psychiatric Status Ra | 1990 |
Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia.
Topics: Aged; Chronic Disease; Dyskinesia, Drug-Induced; Homovanillic Acid; Humans; Male; Middle Aged; Neuro | 1990 |
Plasma HVA in psychiatric patients: longitudinal studies.
Topics: Homovanillic Acid; Humans; Longitudinal Studies; Psychiatric Status Rating Scales; Schizophrenia; Sc | 1990 |
Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept.
Topics: Adult; Female; Glycols; Haloperidol; Homovanillic Acid; Humans; Male; Methoxyhydroxyphenylglycol; Mi | 1990 |
Sensory gating deficits in psychiatric inpatients: relation to catecholamine metabolites in different diagnostic groups.
Topics: Adult; Arousal; Attention; Bipolar Disorder; Brain; Catecholamines; Depressive Disorder; Evoked Pote | 1990 |
Sensory physiology and catecholamines in schizophrenia and mania.
Topics: Adult; Arousal; Bipolar Disorder; Dopamine; Electroencephalography; Evoked Potentials, Auditory; Fem | 1990 |
Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history.
Topics: Adult; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Phenylacetates; | 1985 |
CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide.
Topics: Adult; Chronic Disease; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; | 1985 |
Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls.
Topics: Adult; Amino Acids; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Methoxyhydrox | 1985 |
Brain ventricular size and CSF monoamine metabolites in an adolescent inpatient population.
Topics: Adolescent; Adult; Age Factors; Cerebral Ventricles; Child; Dilatation, Pathologic; Female; Homovani | 1985 |
[Monoamine metabolite levels in cerebrospinal fluid of schizophrenic patients].
Topics: Adolescent; Adult; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; S | 1985 |
Correlates of lateral ventricular size in chronic schizophrenia, II: biological measures.
Topics: Adult; Apomorphine; Brain; Cerebral Ventricles; Chronic Disease; Growth Hormone; Homovanillic Acid; | 1986 |
Neurochemical findings in the cerebrospinal fluid of schizophrenic patients with tardive dyskinesia and neuroleptic-induced parkinsonism.
Topics: Adult; Aged; Antipsychotic Agents; Catecholamines; Dopamine; Dyskinesia, Drug-Induced; Epinephrine; | 1986 |
CSF levels of receptor-active endorphins in schizophrenic patients: correlations with symptomatology and monoamine metabolites.
Topics: Adolescent; Adult; Antipsychotic Agents; Endorphins; Female; Homovanillic Acid; Humans; Hydroxyindol | 1986 |
Cerebrospinal fluid correlates of suicide attempts and aggression.
Topics: Aggression; Animals; Bipolar Disorder; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindole | 1986 |
Suicide and aggression in schizophrenia. Neurobiologic correlates.
Topics: Aggression; Brain; Cerebral Ventricles; Dexamethasone; Homovanillic Acid; Humans; Hydrocortisone; Hy | 1986 |
Monoamines and their metabolites in cerebrospinal fluid of patients with senile dementia of Alzheimer type using high performance liquid chromatography and gas chromatography-mass spectrometry.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biogenic Amines; Chromatography, High Pressure Liquid; G | 1987 |
CSF creatinine in schizophrenia.
Topics: Adult; Blood-Brain Barrier; Creatinine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; | 1988 |
The effect of electroconvulsive therapy on CSF amine metabolites in schizophrenic patients.
Topics: Adult; Aged; Electroconvulsive Therapy; Female; Glycols; Homovanillic Acid; Humans; Hydroxyindoleace | 1988 |
Seasonal changes of CSF monoamine metabolites in psychiatric patients: what is the source?
Topics: Bipolar Disorder; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mental D | 1988 |
Corrections to a 1980 article on CSF monoamine metabolites.
Topics: 3,4-Dihydroxyphenylacetic Acid; Depressive Disorder; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1989 |
CSF neurochemical study of tardive dyskinesia.
Topics: Acetylcholinesterase; Dyskinesia, Drug-Induced; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; | 1989 |
CSF norepinephrine in schizophrenia is elevated prior to relapse after haloperidol withdrawal.
Topics: Adult; Chromatography, High Pressure Liquid; Chronic Disease; Haloperidol; Homovanillic Acid; Humans | 1989 |
Clozapine pharmacology and tardive dyskinesia.
Topics: Adolescent; Adult; Clozapine; Dibenzazepines; Dyskinesia, Drug-Induced; Epinephrine; Female; Homovan | 1989 |
Plasma HVA, neuroleptics, and dopaminergic plasticity.
Topics: Antipsychotic Agents; Brain; Chronic Disease; Homovanillic Acid; Humans; Neuronal Plasticity; Recept | 1989 |
Persistence of cyclicity of the plasma dopamine metabolite, homovanillic acid, in neuroleptic treated schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Circadian Rhythm; Dopamine; Homovanillic Acid; Humans; Hydr | 1989 |
The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia.
Topics: Antipsychotic Agents; Brain; Dopamine; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; F | 1989 |
Plasma homovanillic acid in schizophrenics: supportive evidence for the two-subtype hypothesis.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Female; Homovanillic Acid; Humans; Male; Schizoph | 1989 |
Multivariate analysis of monoamine indices in patients with chronic schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Brain; Dopamine; Dopamine beta-Hydroxylase; Dyskinesia, | 1989 |
Cerebrospinal fluid magnesium and calcium related to amine metabolites, diagnosis, and suicide attempts.
Topics: Adjustment Disorders; Adult; Aged; Calcium; Depressive Disorder; Dexamethasone; Female; Homovanillic | 1985 |
Atrophy limited to the third ventricle in chronic schizophrenic patients. Report of a controlled series.
Topics: Adult; Atrophy; Brain; Cerebellum; Cerebral Cortex; Cerebral Ventricles; Female; Homovanillic Acid; | 1985 |
Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antipsychotic Agents; Chronic Disease; Dopamine; Female; Halo | 1985 |
Free and conjugated plasma homovanillic acid in schizophrenic patients.
Topics: Adolescent; Adult; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Humans; Male; Mi | 1989 |
Plasma and CSF HVA before and after pharmacological treatment.
Topics: Adult; Brain; Desipramine; Female; Homovanillic Acid; Humans; Lithium; Male; Psychiatric Status Rati | 1989 |
Plasma homovanillic acid as a predictor of response to fluphenazine treatment.
Topics: Adult; Fluphenazine; Homovanillic Acid; Humans; Male; Middle Aged; Schizophrenia | 1989 |
Specificity of plasma HVA response to dexamethasone in psychotic depression.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Depressive Disorder; Dexamethasone; Female; | 1989 |
Chemical and structural changes in the brain in patients with movement disorder.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Antipsychotic Agents; Brain; Choline O-Acetyltransfer | 1985 |
Prediction of response to neuroleptic drug therapy in schizophrenia.
Topics: Antipsychotic Agents; Electroencephalography; Genetic Variation; Homovanillic Acid; Humans; Kinetics | 1985 |
Down-regulation of central dopamine receptors in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Apomorphine; Female; Growth Hormone; Homovanillic Acid; Hum | 1985 |
Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
Topics: Adult; Antipsychotic Agents; Apomorphine; Growth Hormone; Homovanillic Acid; Humans; Male; Prolactin | 1985 |
CSF dopamine turnover and positive schizophrenic symptoms after withdrawal of long-term neuroleptic treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Antipsychotic Agents; Brain; Chronic Disease; Dopamine; Femal | 1985 |
Changes in mental condition, hyperkinesias and biochemical parameters after withdrawal of chronic neuroleptic treatment.
Topics: Adult; Antipsychotic Agents; Dopamine beta-Hydroxylase; Dyskinesia, Drug-Induced; Female; Homovanill | 1985 |
Neuroleptics, dopamine, and schizophrenia.
Topics: Adult; Animals; Antipsychotic Agents; Brain; Dopamine; Fluphenazine; Homovanillic Acid; Humans; Male | 1986 |
Remoxipride in schizophrenia. A preliminary report.
Topics: Adult; Antipsychotic Agents; Benzamides; Female; Homovanillic Acid; Humans; Male; Middle Aged; Pilot | 1986 |
[Physiopathologic chemistry of the schizophrenic brain].
Topics: Adult; Aged; Aged, 80 and over; Brain; Dopamine; Female; Homovanillic Acid; Humans; Male; Middle Age | 1987 |
Serum homovanillic acid concentrations in carbamazepine-treated chronic schizophrenics.
Topics: Adult; Carbamazepine; Chronic Disease; Homovanillic Acid; Humans; Male; Receptors, Dopamine; Schizop | 1989 |
An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET.
Topics: Acute Disease; Adolescent; Adult; Female; Hemodynamics; Homovanillic Acid; Humans; Male; Middle Aged | 1988 |
Effect of trifluoperazine on CSF and plasma HVA levels in schizophrenic subjects.
Topics: Adult; Dopamine; Female; Homovanillic Acid; Humans; Male; Schizophrenia; Schizophrenic Psychology; T | 1988 |
Dopamine metabolism and disposition in schizophrenic patients. Studies using debrisoquin.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Aged; Blood Platelets; Brain; Debrisoquin; Dopamine; Homovani | 1988 |
A comparison of plasma homovanillic acid concentrations in schizophrenic patients and normal controls.
Topics: Adult; Brain; Chronic Disease; Circadian Rhythm; Dopamine; Homovanillic Acid; Hospitalization; Human | 1988 |
Plasma homovanillic acid as a predictor of response to neuroleptics.
Topics: Adult; Dopamine; Female; Haloperidol; Homovanillic Acid; Humans; Male; Probability; Psychiatric Stat | 1988 |
Plasma homovanillic acid levels and subtyping of schizophrenia.
Topics: Adolescent; Adult; Female; Haloperidol; Homovanillic Acid; Humans; Male; Middle Aged; Prognosis; Sch | 1988 |
Effects of debrisoquin on plasma homovanillic acid concentration in schizophrenic patients.
Topics: Adult; Debrisoquin; Homovanillic Acid; Humans; Isoquinolines; Male; Schizophrenia | 1987 |
Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients.
Topics: Adult; Debrisoquin; Drug Therapy, Combination; Haloperidol; Homovanillic Acid; Humans; Isoquinolines | 1987 |
Structural brain pathology in schizophrenia revisited. Prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid.
Topics: Adult; Atrophy; Cerebral Cortex; Cerebral Ventricles; Cerebral Ventriculography; Female; Homovanilli | 1987 |
Elevation of plasma homovanillic acid level can be detected within four hours after initiation of haloperidol treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Female; Haloperidol; Homovanillic Acid; Humans; Male; Prolact | 1987 |
Increase in human urine homovanillic acid concentration after neuroleptic treatment is the same with or without debrisoquin administration.
Topics: Brain; Debrisoquin; Dopamine; Haloperidol; Homovanillic Acid; Humans; Isoquinolines; Male; Schizophr | 1987 |
Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adolescent; Adult; Atrophy; Cerebral Cortex; Dopamine; Female; Homov | 1986 |
Cerebrospinal fluid HVA, central brain atrophy, and clinical state in schizophrenia.
Topics: Adult; Atrophy; Brain; Cerebral Ventricles; Chronic Disease; Female; Homovanillic Acid; Humans; Male | 1986 |
Short-term haloperidol administration acutely elevates human plasma homovanillic acid concentration.
Topics: Brain; Dopamine; Haloperidol; Homovanillic Acid; Humans; Schizophrenia; Time Factors | 1987 |
Central catecholamines, cognitive impairment, and affective state in elderly schizophrenics and controls.
Topics: 3,4-Dihydroxyphenylacetic Acid; Affect; Aged; Catecholamines; Cognition; Homovanillic Acid; Humans; | 1987 |
Biochemical alterations produced by neuroleptics in man: studies of plasma homovanillic acid in schizophrenic patients.
Topics: Adult; Female; Fluphenazine; Genetic Variation; Homovanillic Acid; Humans; Male; Schizophrenia; Time | 1987 |
Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients.
Topics: Adult; Apomorphine; Haloperidol; Homovanillic Acid; Humans; Male; Middle Aged; Psychotic Disorders; | 1985 |
Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
Topics: Apomorphine; Bromocriptine; Growth Hormone; Homovanillic Acid; Humans; Levodopa; Male; Metoclopramid | 1985 |
Plasma homovanillic acid concentration and the severity of schizophrenic illness.
Topics: Adult; Haloperidol; Homovanillic Acid; Humans; Male; Phenylacetates; Schizophrenia | 1985 |
Evidence for a daily rhythm of plasma HVA in normal controls but not in schizophrenic patients.
Topics: Adult; Circadian Rhythm; Female; Homovanillic Acid; Humans; Male; Phenylacetates; Schizophrenia; Tim | 1985 |
Postmortem central catecholamines and antemortem cognitive impairment in elderly schizophrenics and controls.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Brain Chemistry; Catecholamines; Cognition; Dementia; Dopamine | 1985 |
Further studies on the mechanism of antipsychotic action: potentiation by alpha-methyltyrosine of thioridazine effects in chronic schizophrenics.
Topics: Chronic Disease; Drug Synergism; Evaluation Studies as Topic; Female; Homovanillic Acid; Humans; Hyd | 1973 |
Use of cerebrospinal fluid drawn at pneumoencephalography in the study of monoamine metabolism in man.
Topics: Adolescent; Adult; Brain Diseases; Epilepsy, Temporal Lobe; Epilepsy, Tonic-Clonic; Female; Homovani | 1974 |
[Effect of clozapine on the excretion of 3-methoxy-4-hydroxy-phenylglycol, homovanillic acid and 5-hydroxy-indole acetic acid in urine and cerebrospinal fluid].
Topics: Azepines; Bipolar Disorder; Dopamine beta-Hydroxylase; Glycols; Homovanillic Acid; Humans; Hydroxyin | 1974 |
Amphetamine psychosis: behavioral and biochemical aspects.
Topics: Adolescent; Adult; Affect; Alcoholism; Amphetamine; Brain; Cognition Disorders; Delusions; Depressio | 1974 |
Mass fragmentometric determination of homovanillic acid in lumbar cerebrospinal fluid of schizophrenic patients during treatment with antipsychotic drugs.
Topics: Adult; Age Factors; Bipolar Disorder; Brain; Chlorpromazine; Chromatography, Gas; Deuterium; Dopamin | 1974 |
Simultaneous quantification of homovanillic acid and 5-hydroxyindoleacetic acid in cerebrospinal fluid by mass fragmentography.
Topics: Gas Chromatography-Mass Spectrometry; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Schizophr | 1974 |
Dopamine-beta-hydroxylase: evidence for increased activity in sympathetic neurons during psychotic states.
Topics: Bipolar Disorder; Dopamine; Dopamine beta-Hydroxylase; Homovanillic Acid; Humans; Male; Methoxyhydro | 1973 |
[Pharmacological and neurochemical effects of clozapine (Leponex): new aspects in the drug therapy of schizophrenia].
Topics: Animals; Brain Stem; Caudate Nucleus; Corpus Striatum; Dibenzazepines; Dibenzoxazepines; Dopamine; E | 1973 |
Mass fragmentographic analysis of homovanillic acid and its homoiso analogue in cerebrospinal fluid using the alpha-dideutero acid as internal standard.
Topics: Deuterium; Homovanillic Acid; Humans; Isomerism; Mass Spectrometry; Methods; Phenylacetates; Schizop | 1974 |
Central dopamine turnover in schizophrenic syndromes.
Topics: Affective Symptoms; Chlorpromazine; Dopamine; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic | 1974 |
Antipsychotic efficacy of clozapine in correlation to changes in catecholamine metabolism in man.
Topics: Bipolar Disorder; Carbon Radioisotopes; Catecholamines; Chromatography, Gas; Dibenzazepines; Dopamin | 1974 |